Patient	O
has	O
history	B
of	I
loose	O
or	O
watery	B
stools	I

Patient	O
has	O
both	O
clinically	B
significant	I
findings	I
and	O
unexplained	B
clinically	B
significant	I
alarm	I
symptoms	I

Patient	O
has	O
symptoms	O
of	O
or	O
been	O
diagnosed	O
with	O
a	O
medical	B
condition	I
that	O
may	O
contribute	O
to	O
abdominal	B
pain	I

Patient	O
has	O
any	O
protocol	B
-	I
excluded	I
or	O
clinically	B
significant	I
medical	O
or	O
surgical	B
history	I
that	O
could	B
confound	I
the	I
study	I
assessments	I

Patient	O
meets	O
protocol	B
criteria	I
for	O
diagnosis	O
of	O
IBS	B
-	I
C	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
bloating	I
and	O
abdominal	B
girth	I

Patients	O
with	O
liver	B
cirrhosis	I
,	O
Hepatocellular	B
Carcinoma	I
or	O
AFP	B
>	B
2	I
ULN	I
or	O
other	O
malignancies	B
.	O

Patients	O
with	O
other	O
factors	O
causing	O
liver	B
diseases	I
.	O

Pregnant	O
and	O
lactating	O
women	O
.	O

Patients	O
with	O
concomitant	B
HIV	B
infection	I
or	O
congenital	B
immune	I
deficiency	I
diseases	I
.	O

Patients	O
with	O
diabetes	B
,	O
autoimmune	B
diseases	I
.	O

Patients	O
with	O
important	B
organ	B
dysfunctions	I
.	O

Patients	O
with	O
serious	B
complications	B
(	O
e	O
.	O
g	O
.	O
,	O
infection	B
,	O
hepatic	B
encephalopathy	I
,	O
hepatorenal	B
syndrome	I
,	O
gastrointestinal	B
bleeding	I
.	O
)	O

Patients	O
who	O
receive	O
antineoplastic	O
or	O
immunomodulatory	B
therapy	I
in	O
the	O
past	B
12	I
months	I
.	O

Patients	O
with	O
a	O
previous	O
use	O
of	O
IFN	B
anti	B
hepatitis	I
B	I
virus	I
treatment	O
or	O
have	O
NAs	B
drug	I
resistance	B
.	O

Patients	O
who	O
can	O
'	O
t	O
come	O
back	O
to	O
clinic	O
for	O
follow	O
-	O
up	O
on	O
schedule	O
.	O

CHB	B
patients	O
who	O
had	O
received	O
single	B
NAs	B
for	O
more	B
than	I
12	I
months	I
.	O

Hepatitis	B
B	I
e	I
antigen	I
(	O
HBeAg	B
)	O
-	O
negative	B
.	O

Hepatitis	B
B	I
surface	I
antigen	I
(	O
HBsAg	B
)	O
positive	B
and	O
<	B
1000	I
IU	I
/	I
mL	I
.	O

Hepatitis	B
B	I
virus	I
DNA	I
<	B
100	I
IU	I
/	I
mL	I
.	O

Rest	B
pain	I
or	O
tissue	B
loss	I
due	O
to	O
PAD	B
(	O
Fontaine	B
stage	I
III	B
and	O
IV	B
)	O
,	O

acute	B
lower	B
extremity	I
ischemic	B
event	I
secondary	O
to	O
thromboembolic	B
disease	I
or	O
acute	B
trauma	I
,	O

Walking	B
capacity	I
significantly	B
limited	I
by	O
conditions	O
other	B
than	I
claudication	B
including	O
leg	O
(	O
joint	B
/	O
musculoskeletal	B
,	O
neurologic	B
)	O
and	O
systemic	O
(	O
heart	O
,	O
lung	B
disease	I
)	O
pathology	O
,	O

Current	B
use	I
of	O
either	O
ACE	B
inhibitors	I
or	O
angiotensin	B
II	I
receptor	I
blockers	I
,	O

Chronic	B
kidney	I
disease	I
with	O
estimated	B
Glomerular	I
Filtration	I
Rate	I
<	B
30	I
ml	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
,	O

History	B
of	O
bilateral	B
severe	B
renal	B
artery	I
stenosis	I
and	O
7	O
)	O
History	B
of	O
angioedema	B
related	O
to	O
previous	B
ACE	B
-	I
inhibitor	I
treatment	O
or	O
known	B
hypersensitivity	B
to	O
ramipril	B
or	O
other	O
ACE	B
inhibitors	I
.	O

A	O
positive	B
history	I
of	O
chronic	B
claudication	I
,	O

Exercise	B
-	I
limiting	I
claudication	I
established	O
by	O
history	B
and	O
direct	B
observation	I
during	O
a	O
screening	B
walking	I
test	I
administered	O
by	O
the	O
evaluating	O
vascular	O
surgeon	O
,	O

Arterial	B
occlusive	I
disease	I
per	O
ankle	B
Brachial	I
index	I
measurements	I
and	O
/	O
or	O
other	O
imaging	B
modalities	I
,	O

Stable	B
blood	B
pressure	I
regimen	I
,	O
stable	B
lipid	B
regimen	I
,	O
stable	B
diabetes	B
regimen	I
and	O
risk	B
factor	I
control	I
for	B
6	I
weeks	I
.	O

Rheumatoid	B
arthritis	I

Diabetes	B
or	O
immediate	O
family	O
history	O
of	O
diabetes	B

Coronary	B
artery	I
disease	I

Congestive	B
heart	I
failure	I

Pulmonary	B
disorders	I
,	O
including	O
COPD	B
and	O
asthma	B

Malabsorptive	B
GI	I
disease	I
,	O
such	O
as	O
celiac	B
disease	I
,	O
or	O
gastric	B
bypass	I

Significant	B
hepatic	B
disease	I

Renal	B
insufficiency	I
(	O
eGFR	B
<	B
60	I
mL	I
/	I
kg	I
/	I
min	I
)	O

Anemia	B
(	O
hematocrit	B
<	B
34	I
%	I
)	O
as	O
measured	O
at	O
screening	O
visit	O

Pregnant	B
females	B

Consumption	O
of	O
daily	B
medications	B
that	B
alter	I
glucose	I
metabolism	I
of	I
GI	I
function	I
(	O
glucocorticoids	B
,	O
psychotropics	B
,	O
narcotics	B
,	O
metoclopramide	B
)	O

Consumption	O
or	O
injection	B
of	O
insulin	B

Apparent	O
sensitivity	B
to	O
any	O
of	O
the	O
study	B
peptides	I
as	O
determined	O
by	O
the	O
skin	B
test	I

Diagnosis	O
or	O
h	O
/	O
o	O
PTSD	B
,	O
depression	B
,	O
substance	B
use	I
,	O
mental	B
health	I
problems	I
,	O
sleep	B
disorders	I
,	O
HPA	B
disruption	I
and	O
/	O
or	O
TBI	B

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
=	B
35	I
kg	I
/	I
m2	I

HbA1c	B
=	B
5	I
.	I
7	I
%	I

Ability	O
to	O
speak	O
and	O
understand	O
English	O

Revision	O
cases	O

Uncontrolled	B
bleeding	B
tendency	I
(	O
prothrombin	B
conc	O
.	O
Less	B
than	I
70	I
%	I
)	O

History	B
of	O
deep	B
venous	I
thrombosis	I

Sever	B
liver	B
impairment	I
(	O
liver	B
failure	I
)	O

Sever	B
renal	B
impairment	I
(	O
S	O
.	O
creatinine	B
more	B
than	I
3	I
)	O

Primary	B
total	B
hip	I
arthroplasty	I
(	O
THA	B
)	O

Allergic	B
to	O
study	B
drugs	I

Antiemetics	B
or	O
steroids	B
use	I
within	O
24	O
hrs	O
prior	O
to	O
surgery	B

Dependence	B
upon	I
opioids	I

Insulin	B
dependent	O
Diabetes	B
Mellitus	I

Cardiovascular	O
or	O
pulmonary	B
disease	I

Renal	O
or	O
hepatic	B
insufficiency	I

BMI	B
>	B
=	I
35kg	I
/	I
m2	I

History	B
of	O
motion	B
sickness	I
or	O
PONV	B

Cigarette	O
smoker	O

Conversion	O
to	O
open	B
laparotomy	I
from	O
laparoscopic	B
surgery	I

Pregnants	B

20	B
-	I
70	I
yrs	I
of	O
age	B

ASA	O
(	O
American	B
Society	I
of	I
Anesthesiologists	I
)	O
physical	O
status	O
class	O
I	B
or	I
II	I

Scheduled	O
for	O
gynecological	B
laparoscopic	B
surgery	I

Born	B
prior	B
to	I
34	I
weeks	I

Neonatal	O
intensive	O
care	O
unit	O
admission	O

Serious	B
medical	B
comorbidities	I

Primary	O
substance	O
exposure	O
in	B
-	I
utero	I
was	O
buprenorphine	B
,	O
or	O
was	O
not	B
opioids	B

Born	B
at	O
University	O
of	O
New	O
Mexico	O
Hospital	O

Greater	B
than	I
34	I
weeks	I
gestation	B

Primary	O
in	B
-	I
utero	I
drug	O
exposure	O
was	O
opioids	B
other	B
than	O
buprenorphine	B

Maternal	B
or	O
infant	B
urine	B
drug	I
screen	I
positive	B
for	O
methadone	B
and	O
/	O
or	O
opioids	B
on	O
admission	O

Current	B
or	O
planned	O
pregnancy	B

History	B
of	O
neuropathic	B
pain	I
,	O
chronic	B
pain	I
syndrome	I
,	O
or	O
preoperative	B
use	O
of	O
narcotic	O
or	O
neuropathic	B
pain	I
medicine	I

Radiographic	B
signs	O
of	O
osteoarthritis	B
(	O
>	O
Tonis	B
grade	I
1	O
)	O

Inability	B
to	O
attend	O
follow	O
up	O
visits	O

Documented	O
allergy	B
to	O
local	B
anesthetic	I

Scheduled	O
for	O
arthroscopic	B
labral	I
repair	I
with	O
or	O
without	O
osteoplasty	B
of	O
the	O
hip	B
.	O

18	B
to	I
50	I
years	I
old	B

American	O
Society	O
of	O
Anesthesiologists	O
Physical	O
Status	O
(	O
ASA	B
PS	I
)	O
score	O
of	O
I	B
or	I
II	I
.	O

Chronic	B
HCV	I
Infection	I
with	O
Genotype	B
2	I
or	O
3	O

Amiodarone	B
.	O

Subjects	O
previously	O
treated	O
with	O
amiodarone	O
must	O
have	O
stopped	O
the	O
amiodarone	O
at	B
least	I
60	I
days	I
prior	I
to	I
day	I
1	I
of	I
SOF	I
/	I
LDV	I
FDC	I

Carbamazepine	B
,	O
phenytoin	B
,	O
phenobarbital	B
,	O
oxcarbazepine	B

Rifabutin	B
,	O
rifampin	B
or	O
rifapentine	B

HIV	O
regimens	O
containing	O
tenofovir	B
or	O
tipranavir	B
/	I
ritonavir	I

St	B
.	I
John	I
'	I
s	I
wort	I

Rosuvastatin	B

Have	O
any	O
serious	O
or	O
active	O
medical	O
or	O
psychiatric	O
illness	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
interfere	O
with	O
subject	O
treatment	O
,	O
assessment	O
,	O
or	O
compliance	O

History	O
of	O
hepatic	B
encephalopathy	I
or	O
variceal	B
hemorrhage	I

Hepatitis	B
B	I
surface	I
antigen	I
positive	B

Hemoglobin	B
(	O
Hb	B
)	O
<	B
8	I
g	I
/	I
dL	I

Platelets	B
=	B
50	I
,	I
000	I
/	I
mm3	I

alanine	B
aminotransferase	I
(	O
ALT	B
)	O
,	O
aspartase	B
aminotransferase	I
(	O
AST	B
)	O
,	O
or	O
alkaline	B
phosphatase	I
=	B
10	I
times	I
upper	I
limit	I
of	I
normal	I
(	O
ULN	O
)	O

Total	B
bilirubin	I
>	B
3	I
mg	I
/	I
dl	I

Severe	B
renal	B
impairment	I
creatinine	B
clearance	I
(	O
CrCl	B
)	O
,	O
i	O
.	O
e	O
.	O
<	B
30	I
mL	I
/	I
min	I
.	O

History	O
of	O
major	B
organ	I
transplantation	I
with	O
an	O
existing	B
functional	I
graft	I
.	O

History	O
of	O
clinically	B
-	I
significant	I
drug	B
allergy	I
to	O
nucleoside	B
/	O
nucleotide	B
analogs	I
.	O

Pregnant	O
women	O
or	O
women	O
planning	O
to	O
become	O
pregnant	O

Women	O
who	O
are	O
breastfeeding	O

Active	O
or	O
recent	O
history	O
(	O
=	B
1	I
year	I
)	O
of	O
drug	O
or	O
alcohol	O
abuse	O

Chronic	B
HCV	I
Infection	I
of	O
Genotype	B
1	I
,	O
4	O
,	O
5	O
,	O
or	O
6	O

HCV	B
RNA	I
>	B
103	I
IU	I
/	I
mL	I
at	B
screening	I

18	O
years	O
of	O
age	B
or	O
older	O

Diagnosis	O
of	O
chronic	B
HCV	I
infection	I
,	O
defined	O
as	O
positive	B
HCV	B
antibody	I
or	O
HCV	B
RNA	I
more	B
than	I
6	I
months	I
prior	I
to	I
screening	I
OR	O
an	O
assessment	B
of	I
fibrosis	I
F2	B
or	I
greater	I
prior	B
to	I
screening	I
.	O

NYHA	B
Class	B
III	I
:	O
Subjects	O
with	O
cardiac	O
disease	O
resulting	O
in	O
marked	O
limitation	O
of	O
physical	O
activity	O
.	O
They	O
are	O
comfortable	O
at	O
rest	O
.	O
Less	O
than	O
ordinary	O
physical	O
activity	O
causes	O
fatigue	O
,	O
palpitation	O
,	O
dyspnea	O
,	O
or	O
anginal	O
pain	O
.	O

NYHA	B
Class	B
IV	I
:	O
Patient	O
with	O
cardiac	O
disease	O
resulting	O
in	O
inability	O
to	O
carry	O
on	O
any	O
physical	O
activity	O
without	O
discomfort	O
.	O
Symptoms	O
of	O
cardiac	O
insufficiency	O
or	O
of	O
the	O
anginal	O
syndrome	O
may	O
be	O
present	O
even	O
at	O
rest	O
.	O
If	O
any	O
physical	O
activity	O
is	O
undertaken	O
,	O
discomfort	O
is	O
increased	O
.	O

ejection	B
fraction	I
=	B
30	I
%	I

hospitalized	O
for	O
heart	B
failure	I
in	B
last	I
12	I
months	I

ILD	B
criteria	I
:	O
diagnosis	O
of	O
interstitial	B
lung	I
disease	I
with	O
chronic	O
supplemental	O
oxygen	O
requirement	O
at	B
rest	I
and	O
/	O
or	O
with	B
exertion	I
.	O

Forced	B
expiratory	I
volume	I
(	O
FEV1	B
)	O
<	B
30	I
%	I
predicted	I

OR	O
any	O
FEV1	O
with	O
chronic	O
supplemental	O
oxygen	O
requirement	O
at	B
rest	I
and	O
/	O
or	O
with	B
exertion	I

OR	O
any	O
FEV1	O
with	O
chronic	B
hypercapnia	I
(	O
baseline	O
partial	B
pressure	I
of	I
arterial	I
carbon	I
dioxide	I
[	O
PaCO2	B
]	O
>	B
45	I
)	O

with	O
centre	B
neural	I
system	I
involvement	I

serious	B
complications	B
such	O
as	O
uncontrolled	B
diabetes	B
,	O
gastric	B
ulcer	I
or	O
other	O
serious	B
angiocardiopathy	B
determined	O
by	O
the	O
physician	O

HIV	B
positive	I
or	O
active	B
HBV	I
infection	I
or	O
other	O
uncontrolled	B
systematic	B
infection	I

clinical	O
central	B
nervous	I
dysfunction	I

serious	B
surgery	B
within	B
30	I
days	I

pregnancy	O
or	O
baby	O
nursing	O
period	O
or	O
un	B
-	I
contracepted	B
child	O
bearing	O
period	O
woman	B
.	O

age	B
=	B
65	I
years	I

diagnosis	O
with	O
mantle	B
cell	I
lymphoma	I

Ann	B
Arbor	I
stage	I
II	B
,	O
III	B
or	O
IV	B

ECOG	B
=	B
1	I
or	O
if	O
ECOG	B
=	B
2	I
but	O
recover	B
after	O
pretreatment	B
.	O

Taking	O
other	B
drugs	B
which	O
can	O
influence	O
the	O
lipid	B
profile	I
(	O
eg	O
.	O

Niacin	B
,	O
Fibrates	B
;	O

Serum	B
creatinine	I
level	I
>	B
2	I
.	I
0	I
mg	I
/	I
dL	I

Serum	B
aspartate	I
transaminase	I
>	B
3	I
times	I
upper	I
limit	I
of	I
normal	I

Serum	B
alanine	I
transaminase	I
>	B
3	I
times	I
upper	I
limit	I
of	I
normal	I

Having	O
anaphylactic	B
reaction	I
for	O
Rosuvastatin	B
;	O

Having	O
the	O
other	O
contraindications	B
for	O
Rosuvastatin	B
;	O

Having	O
plan	O
to	O
be	O
pregnant	B
;	O

Having	O
life	O
expectancy	O
less	B
than	I
1	I
year	I

Patients	O
underwent	O
percutaneous	B
coronary	I
intervention	I
with	O
drug	B
-	I
eluting	I
stent	I
;	O

pregnancy	B
,	O

patients	O
under	O
legal	B
custody	I
,	O

patients	O
without	B
health	B
insurance	I
,	O

patients	O
included	O
in	O
another	O
interventional	O
clinical	O
study	O
involving	O
infections	O
or	O
antibiotics	O
and	O
having	O
the	O
same	O
primary	O
parameter	O
,	O

moribund	B
patients	O
,	O

situation	O
in	O
which	O
the	O
procalcitonin	B
concentration	I
could	O
be	O
increased	B
without	O
correlation	O
to	O
an	O
infectious	O
process	O
(	O
poly	B
-	I
traumatised	I
patients	O
,	O

surgical	B
interventions	I
within	O
the	O
last	B
4	I
days	I
,	O

cardiorespiratory	B
arrest	I
,	O

administration	O
of	O
anti	B
-	I
thymocyte	I
globulin	I
,	O

immunodepressed	B
patients	O
(	O
bone	B
marrow	I
transplant	I
patients	O
,	O
patients	O
with	O
severe	B
neutropenia	I
)	O
,	O

patients	O
with	O
an	O
absolute	O
indication	B
for	O
administration	O
of	O
antibiotics	B
at	O
the	O
moment	O
of	O
ICU	O
admission	O
(	O
meningitis	B
,	O
pneumonia	B
)	O
or	O
a	O
chronic	B
infection	I
for	O
which	O
long	B
-	I
term	I
antibiotic	B
treatment	I
is	O
necessary	O
(	O
endocarditis	B
,	O
osteo	B
-	I
articular	I
infections	I
,	O
mediastinitis	B
,	O
deep	B
abscesses	I
,	O
pneumocystis	B
infection	I
,	O
toxoplasmosis	B
,	O
tuberculosis	B
)	O

patients	O
with	O
haemodynamic	B
instability	I
of	O
septic	B
origin	O
or	O
a	O
respiratory	B
insufficiency	I
(	O
defined	O
by	O
a	O
ratio	O
Pa02	B
/	I
Fi02	I
=	B
200	I
mmHg	I
and	O
PEP	B
=	B
5	I
cmH2O	I
)	O

aged	B
18	B
or	I
older	I
,	O

have	O
undergone	O
oro	B
-	I
tracheal	I
intubation	I
for	O
a	O
coma	B
(	O
Glasgow	B
Coma	I
Score	I
below	B
or	I
equal	I
to	I
8	I
)	I
,	O

with	O
mechanical	B
ventilation	I
initiated	O
in	O
the	O
first	B
48	I
hours	I
following	I
hospital	I
admission	I

Any	O
contraindication	B
to	O
neuraxial	B
anesthesia	I
(	O
history	B
of	O
neurologic	B
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
multiple	B
sclerosis	I
,	O
spinal	B
stenosis	I
,	O
central	O
or	O
peripheral	B
neuropathy	I
)	O

Pre	B
-	I
existing	I
/	O
chronic	B
back	B
pain	I

Ester	B
local	I
anesthetic	I
allergy	B
,	O
PABA	B
allergy	B

History	B
of	O
atypical	B
cholinesterase	I
(	O
CP	O
is	O
metabolized	O
by	O
cholinesterase	O
)	O

ASA	B
I	B
and	I
II	I
women	B

18	B
-	I
45	I
yrs	I
old	B

Singleton	B
pregnancy	I

Cervical	B
cerclage	I
1st	O
or	O
2nd	B
trimester	I
of	O
pregnancy	B
undergoing	O
with	O
spinal	B
anesthesia	I

Height	B
150	B
-	I
180	I
cm	I

BMI	B
=	B
40	I
kg	I
/	I
m2	I
.	O

Revision	B
total	I
knee	I
arthroplasty	I

Bilateral	B
total	I
knee	I
arthroplasty	I

Patients	O
with	O
inflammatory	B
arthritis	I

Patients	O
with	O
a	O
body	B
mass	I
index	I
(	O
BMI	B
)	O
>	B
40	I

Allergy	B
to	O
ropivacaine	B
,	O
bupivacaine	B
,	O
or	O
other	O
local	B
anesthetic	I
agents	I

Current	O
use	O
of	O
opioid	B
drugs	O

Patients	O
with	O
a	O
history	O
of	O
total	B
or	O
unicompartmental	B
reconstruction	B
of	O
the	O
affected	B
joint	I

Patients	O
that	O
have	O
had	O
a	O
high	B
tibial	I
osteotomy	I
or	O
femoral	B
osteotomy	I

Patients	O
with	O
neuromuscular	O
or	O
neurosensory	B
deficiency	I
,	O
which	O
would	O
limit	O
the	O
ability	O
to	O
assess	O
pain	O
levels	O

Patients	O
with	O
a	O
systemic	O
or	O
metabolic	B
disorder	I
leading	O
to	O
progressive	B
bone	B
deterioration	I

Patients	O
that	O
are	O
immunologically	B
compromised	I
,	O
or	O
receiving	O
chronic	B
steroids	B
(	O
>	B
30	I
days	I
)	O
,	O
excluding	B
inhalers	B

Patients	O
'	O
bone	O
stock	O
is	O
compromised	O
by	O
disease	O
or	O
infection	O
,	O
which	O
cannot	O
provide	O
adequate	O
support	O
and	O
/	O
or	O
fixation	O
to	O
the	O
prosthesis	O

Patients	O
with	O
knee	B
fusion	I
to	O
the	O
affected	O
joint	O

Patients	O
with	O
an	O
active	O
or	O
suspected	O
latent	O
infection	B
in	O
or	O
about	O
the	O
knee	B
joint	I

Patients	O
that	O
are	O
prisoners	B

Male	B
or	O
non	B
-	O
pregnant	B
female	B
between	O
the	O
ages	B
of	O
18	B
-	I
65	I

Patients	O
willing	O
and	O
able	O
to	O
sign	O
the	O
informed	O
consent	O

Patients	O
able	O
to	O
comply	O
with	O
follow	O
-	O
up	O
requirements	O
including	O
self	O
-	O
evaluations	O

Patients	O
requiring	O
a	O
primary	B
total	I
knee	I
replacement	I

Patients	O
with	O
a	O
diagnosis	O
of	O
osteoarthritis	B
,	O
traumatic	B
arthritis	I
,	O
or	O
avascular	B
necrosis	I

1	O
.	O

Prior	B
Therapy	O
Exposure	O
to	O
chemotherapy	B
or	O
radiotherapy	B
within	B
2	I
weeks	I
prior	I
to	O
entering	O
the	O
study	O
or	O
those	O
who	O
have	O
not	B
recovered	B
from	O
adverse	B
events	I
due	O
to	O
agents	B
administered	O
more	B
than	I
2	I
weeks	I
earlier	I
.	O

Systemic	B
steroids	I
that	O
have	O
not	B
been	O
stabilized	B
(	O
≥	B
5	I
days	I
)	O
to	O
the	O
equivalent	O
of	O
≤	B
10	I
mg	I
/	I
day	I
prednisone	B
prior	B
to	I
the	O
start	O
of	O
the	O
study	O
drugs	O
.	O

No	O
other	B
investigational	I
agents	I
are	O
allowed	O
.	O

2	O
.	O

History	B
of	O
allergic	B
reactions	I
to	O
TGR	B
-	I
1202	I
or	O
carfilzomib	B

3	O
.	O

Uncontrolled	B
inter	B
-	I
current	I
illness	O

4	O
.	O

Pregnant	B
women	B

5	O
.	O

Nursing	B
women	B

6	O
.	O

Current	B
malignancy	B
or	O
history	B
of	I
a	I
prior	I
malignancy	B

7	O
.	O

Patient	O
known	O
to	O
be	O
Human	B
Immunodeficiency	I
Virus	I
(	I
HIV	I
)	I
-	O
positive	B

8	O
.	O

Active	O
Hepatitis	B
A	I
,	O
Hepatitis	B
B	I
,	O
or	O
Hepatitis	B
C	I
infection	O

Phase	O
I	O
:	O
Patients	O
must	O
have	O
histologically	B
confirmed	B
R	B
/	I
R	I
NHL	B
or	O
HL	B
(	O
defined	O
by	O
WHO	B
criteria	I
)	O
.	O

Patients	O
with	O
chronic	B
lymphocytic	I
leukemia	I
(	I
CLL	I
)	I
and	O
small	B
lymphocytic	I
lymphoma	I
(	I
SLL	I
)	I
are	O
eligible	O
.	O

In	O
addition	O
,	O
patients	O
with	O
NHL	B
other	B
than	I
diffuse	B
large	I
B	I
cell	I
lymphomas	I
(	I
DLBCL	I
)	I
must	O
have	O
received	O
at	B
least	I
2	I
prior	B
therapies	B
.	O

Patients	O
with	O
DLBCL	B
and	O
HL	B
will	O
be	O
eligible	O
if	O
there	O
is	O
no	B
available	O
standard	B
therapy	I
.	O

Phase	O
II	O
:	O
Patients	O
must	O
have	O
histologically	B
confirmed	B
R	B
/	I
R	I
NHL	B
(	O
as	O
defined	O
by	O
WHO	B
criteria	I
)	O
.	O

Patients	O
with	O
NHL	B
other	B
than	I
diffuse	B
large	I
B	I
cell	I
lymphomas	I
(	I
DLBCL	I
)	I
must	O
have	O
received	O
at	B
least	I
2	I
prior	B
therapies	B
.	O

Patients	O
with	O
DLBCL	B
will	O
be	O
eligible	O
if	O
there	O
is	O
no	B
available	O
standard	B
therapy	I
.	O

Must	O
have	O
received	O
front	B
line	I
chemotherapy	B
.	O

No	O
upper	O
limit	O
for	O
the	O
number	O
of	O
prior	O
therapies	O

Evaluable	B
Disease	B
in	B
the	I
Phase	I
I	I
,	O
and	O
measurable	B
disease	O
in	B
the	I
Phase	I
II	I

Age	B
>	B
18	I
years	I

ECOG	B
performance	I
status	I
<	B
2	I

Patients	O
must	O
have	O
adequate	B
organ	O
and	O
marrow	B
function	I

Adequate	B
Contraception	B

Ability	O
to	O
understand	O
and	O
the	O
willingness	O
to	O
sign	O
a	O
written	O
informed	O
consent	O
document	O

History	B
of	O
curettage	B
or	O
other	O
intrauterine	B
surgery	I

History	B
of	O
post	B
-	I
abortion	I
complication	I
or	O
infection	O

Subject	O
has	O
curettage	B
for	O
retained	B
product	I
after	O
second	B
trimester	I
abortion	B

Anaphylactic	B
reaction	I
to	O
a	O
previous	B
dose	O
of	O
influenza	B
vaccine	I
or	O
to	O
any	O
of	O
its	B
components	I

Known	O
Immunoglobulin	B
E	I
(	I
IgE	I
)	I
-	I
mediated	I
hypersensitivity	I
to	O
eggs	B
manifested	O
as	O
hives	B
,	O
swelling	B
of	I
the	I
mouth	I
and	O
throat	O
,	O
difficulty	B
in	I
breathing	I
,	O
hypotension	B
,	O
or	O
shock	B

Guillain	B
-	I
Barré	I
syndrome	I
within	O
eight	O
weeks	O
of	O
a	O
previous	B
influenza	B
vaccine	I

Use	O
of	O
aspirin	B
or	O
salicylate	B
-	I
containing	I
products	I
within	B
30	I
days	I
before	I
enrollment	I

Household	B
members	I
of	O
children	B
in	O
Group	B
A	I

Healthy	B
children	B
aged	B
6	B
months	I
to	I
72	I
months	I

beta	B
blocker	I

supraventricular	B
rhythm	I
disorder	I

previous	B
history	I
of	O
respiratory	B
disease	I
other	B
than	I
COPD	B

diabetes	B

autonomic	B
dysfunction	I

dysautonomia	B

renal	B
failure	I

long	B
-	I
term	I
oxygen	I
therapy	I

history	B
of	O
psychiatric	B
illness	I

patients	O
with	O
FEV1	B
/	I
FVC	I
<	B
70	I
%	I

Non	O
-	O
English	O
speakers	O

Height	B
<	B
4	I
'	I
11	I
"	I

BMI	O
>	B
40	I
Kg	I
/	I
mm	I

Antiemetic	B
drug	I
use	O
in	O
the	O
24	O
hours	O
prior	O
to	O
cesarean	B
delivery	I
,	O

Hypertensive	B
diseases	I
of	I
pregnancy	I

Chronic	B
hypertension	I
receiving	O
antihypertensive	B
treatment	I

Any	O
other	O
physical	O
or	O
psychiatric	O
condition	O
that	O
may	O
impair	O
their	O
ability	O
to	O
cooperate	O
with	O
study	O
data	O
collection	O
.	O

Pregnant	B

American	B
Society	I
of	I
Anesthesiologists	I
risk	I
classification	I
I	B
and	I
II	I

Age	B
>	B
18	I
years	I

Non	B
-	I
laboring	I

Patients	O
with	O
elective	B
cesarean	B
sections	I

History	O
of	O
sensitivity	B
to	O
study	B
medications	I
or	O
any	O
of	O
their	O
excipients	O

RA	B
cohort	O
:	O
Previous	O
intolerance	B
to	O
MTX	B

Current	B
treatment	O
with	O
antiplatelet	B
therapy	I

Absolute	O
indication	O
for	O
anti	B
-	I
platelet	I
therapy	I

Need	O
for	O
chronic	B
oral	I
anticoagulant	I
therapy	I

Severe	B
hepatic	I
impairment	I
(	O
eg	O
,	O
ascites	B
and	O
/	O
or	O
clinical	O
signs	O
of	O
coagulopathy	B
)	O

Renal	B
failure	I
(	O
eGFR	B
<	B
30	I
or	O
requiring	O
dialysis	B
)	O

A	O
known	O
bleeding	B
diathesis	I
,	O
hemostatic	O
or	O
coagulation	B
disorder	I
,	O
or	O
prior	B
major	B
bleeding	I

Prior	B
stroke	B

Active	B
pathological	B
bleeding	I

History	B
of	O
intracranial	B
haemorrhage	I

Life	B
expectancy	I
<	B
12	I
months	I
based	O
on	O
investigator	O
'	O
s	O
judgement	O

Patients	O
considered	O
to	O
be	O
at	O
risk	O
of	O
bradycardic	B
events	I
(	O
e	O
.	O
g	O
.	O
,	O
known	O
sick	B
sinus	I
syndrome	I
or	O
second	O
or	O
third	B
degree	I
atrioventricular	I
[	I
AV	I
)	I
]	I
block	I
)	O
unless	B
already	O
treated	O
with	O
a	O
permanent	B
pacemaker	I

Anemia	B
(	O
hematocrit	B
<	B
27	I
%	I
)	O

Platelet	B
count	I
<	B
100	I
,	I
000	I
/	I
ml	I

Concomitant	O
use	O
of	O
strong	B
CYP	I
3A	I
inhibitors	I
or	O
inducers	O

History	B
of	O
thrombocytopenia	B
or	O
neutropenia	B

Pregnant	B
or	O
nursing	B
women	B
,	O
or	O
females	B
with	O
a	O
positive	B
pregnancy	B
test	I
at	B
screening	I

Females	B
of	O
child	B
bearing	I
potential	I
not	B
using	O
acceptable	B
method	O
of	O
birth	O
control	O
prior	O
to	O
or	O
during	B
study	I

Concern	O
for	O
inability	O
of	O
the	O
patient	O
to	O
comply	O
with	O
study	O
procedures	O
and	O
/	O
or	O
follow	O
up	O
(	O
eg	O
,	O
alcohol	O
or	O
drug	B
abuse	I
)	O

RA	B
cohort	O
:	O
Receiving	O
MTX	B
at	O
stable	B
doses	I
of	O
10	B
to	I
25	I
mg	I
weekly	I
for	B
at	I
least	I
12	I
weeks	I
,	O
Have	O
a	O
DAS28	B
of	O
3	B
.	I
2	I
or	I
higher	I
(	O
The	O
level	O
of	O
disease	O
activity	O
is	O
considered	O
to	O
be	O
low	O
if	O
the	O
DAS28	O
is	O
3	O
.	O
2	O
or	O
less	O
)	O
(	O
Prevoo	O
et	O
al	O
.	O
,	O
1995	O
)	O

OA	B
cohort	O
:	O
Diagnosis	O
of	O
osteoarthritis	B
made	O
by	O
physician	O
.	O

Fasting	B
plasma	I
glucose	I
>	B
7	I
,	I
0	I
mM	I
,	O
HbA1c	B
>	B
48	I
mmol	I
/	I
mol	I
3	O
months	O
after	O
RYGB	B
.	O

Dysregulated	B
thyroid	B
diseases	I
,	O
use	O
of	O
antithyroid	B
treatment	I
.	O

Late	B
diabetic	I
complications	I
as	O
retinopathy	B
,	O
renal	B
insufficiency	I
,	O
neuropathy	B
or	O
previous	B
pancreatitis	B
.	O

Complications	B
to	O
RYGB	B
.	O

Documented	O
reactive	B
hypoglycaemia	I
,	O
severe	B
dumping	B
(	O
vomiting	B
,	O
diarrhea	B
,	O
severe	B
abdominal	B
pain	I
after	B
food	I
intake	I
)	O
.	O

Cholecystectomy	B

Uncomplicated	B
RYGB	B
performed	O
minimum	B
3	I
months	I
prior	I
to	I
the	I
study	I
.	O

Fasting	B
plasma	I
glucose	I
<	B
7	I
,	I
0	I
mM	I
,	O
HbA1c	B
<	B
48	I
mmol	I
/	I
mol	I
3	O
months	O
after	O
RYGB	B

Intranasal	B
steroid	B
use	O
within	B
the	I
last	I
three	I
months	I

Current	B
systemic	B
steroid	B
use	O

Prior	B
septal	B
surgery	I

Individuals	O
who	O
are	O
pregnant	B
or	O
actively	B
breastfeeding	O

Age	B
greater	B
than	I
18	I

NOSE	B
score	I
greater	B
than	I
55	I

Nasal	B
septal	I
deviation	I
on	O
exam	O

Patients	O
who	O
have	O
Tacrolimus	B
trough	O
level	O
resulted	O
as	O
2	B
ng	I
/	I
mg	I
at	O
the	O
baseline	O
.	O

Patients	O
who	O
are	O
on	O
steroid	B
therapy	O
due	O
to	O
positive	B
result	O
of	O
acute	B
rejection	I
test	I
before	O
the	O
baseline	O
.	O

Patients	O
who	O
have	O
received	O
a	O
transplant	B
besides	O
liver	B
.	O

Patients	O
who	O
are	O
allergic	B
to	O
IP	B
or	O
macrolide	B
compounds	O
.	O

Patients	O
who	O
are	O
on	O
cyclosporine	B
,	O
bosentan	B
,	O
or	O
potassium	B
sparing	I
diuretic	I
.	O

Patients	O
with	O
genetic	B
diseases	I
such	O
as	O
galactose	B
intolerance	I
,	O
Lapp	B
lactase	I
deficiency	I
,	O
or	O
glucose	B
-	I
galactose	I
malabsorption	I
.	O

Pregnant	O
or	O
lactating	O
women	O
.	O

Patients	O
not	O
willing	O
to	O
adhere	O
to	O
study	O
procedures	O
/	O
treatments	O
.	O

19	O
years	O
old	B
and	O
above	O
.	O

Patients	O
who	O
previously	O
have	O
received	O
a	O
liver	B
transplant	I
over	O
the	O
last	B
six	I
months	I
and	I
within	I
last	I
three	I
years	I
.	O

Patients	O
who	O
are	O
on	O
Tacrolimus	B
immunosuppressive	O
therapy	O
twice	B
a	I
day	I
for	O
at	B
least	I
two	I
weeks	I
.	O

Patients	O
who	O
have	O
normal	B
liver	B
function	I
and	O
renal	B
function	I
.	O

Patients	O
who	O
have	O
been	O
monitored	O
without	B
complication	B
such	O
as	O
acute	B
rejection	I
.	O

Patients	O
willing	O
to	O
sign	O
his	O
/	O
her	O
consent	O
.	O

dual	B
organ	B
transplant	I

liver	B
transplant	I

Human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
-	I
infected	I

Baseline	B
serology	B
showed	O
a	O
nonreactive	B
RPR	B
test	I

follow	O
-	O
up	O
is	O
inadequate	O

Allergic	B
to	O
penicillin	B

Pregnant	B
woman	B

Early	B
Syphilis	I
Cases	O
Determined	O
to	O
Be	O
Serofast	B
at	O
6	O
Months	O
after	O
Initial	B
Treatment	B

On	O
chronic	O
treatment	B
(	O
i	O
.	O
e	O
.	O
,	O
two	B
weeks	I
or	I
more	I
)	O
with	O
any	O
medication	O
severely	O
affecting	O
oral	O
status	O
(	O
e	O
.	O
g	O
.	O
participants	O
with	O
gingival	B
hypertrophy	I
caused	O
by	O
anti	B
-	I
epileptics	I
,	O
calcium	B
antagonists	I
,	O
cyclosporine	B
and	O
other	O
immunosuppressive	B
)	O
or	O
bone	O
metabolism	O
(	O
e	O
.	O
g	O
.	O
anticoagulant	B
medications	O
,	O
long	O
-	O
standing	O
steroid	B
medications	O
-	O
i	O
.	O
e	O
.	O
equal	O
or	O
more	O
2	O
.	O
5mg	O
of	O
prednisolone	B
a	O
day	O
taken	O
for	O
>	B
3	I
months	I
-	O
,	O
anticonvulsants	B
,	O
immunosuppressants	B
)	O
.	O

Affected	O
by	O
systemic	O
diseases	O
recognized	O
to	O
severely	O
affect	O
bone	O
metabolism	O
(	O
e	O
.	O
g	O
.	O
Cushing	B
'	I
s	I
syndrome	I
,	O
Addison	B
'	I
s	I
disease	I
,	O
diabetes	B
mellitus	I
type	I
1	I
,	O
leukaemia	B
,	O
pernicious	B
anaemia	I
,	O
malabsorption	B
syndromes	I
,	O
chronic	B
liver	I
disease	I
,	O
rheumatoid	B
arthritis	I
)	O
.	O

Knowingly	O
affected	O
by	O
HIV	B
or	O
Hepatitis	B
.	O

History	O
of	O
local	B
radiation	I
therapy	I
in	O
the	O
last	B
five	I
years	I
.	O

Affected	O
by	O
limited	O
mental	O
capacity	O
or	O
language	O
skills	O
such	O
that	O
study	O
information	O
cannot	O
be	O
understood	O
,	O
informed	O
consent	O
cannot	O
be	O
obtained	O
,	O
or	O
simple	O
instructions	O
cannot	O
be	O
followed	O
.	O

Presenting	O
an	O
acute	O
endodontic	O
/	O
periodontal	B
lesion	I
in	O
the	O
neighboring	O
areas	O
to	O
the	O
implant	O
site	O
.	O

Completely	B
edentulous	B

With	O
evident	O
severe	O
atrophy	O
of	O
the	O
alveolar	O
ridge	O
that	O
could	O
preclude	O
an	O
implant	O
placement	O
(	O
e	O
.	O
g	O
.	O
sharp	O
knife	O
edge	O
ridge	O
)	O

Severe	O
bruxism	O
or	O
clenching	O
habits	O

Smokers	B
of	O
>	B
5	I
cigarettes	I
a	I
day	I
.	O

A	O
daily	O
alcohol	O
intake	O
>	B
2	I
units	I
/	I
day	I
.	O

Other	O
severe	O
acute	O
or	O
chronic	O
medical	O
or	O
psychiatric	O
condition	O
or	O
laboratory	O
abnormality	O
which	O
may	O
increase	O
the	O
risk	O
associated	O
with	O
trial	O
participation	O
or	O
investigational	O
product	O
administration	O
or	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
study	O
results	O
and	O
,	O
in	O
the	O
judgment	O
of	O
the	O
investigator	O
,	O
would	O
make	O
the	O
participant	O
inappropriate	O
for	O
entry	O
into	O
this	O
trial	O
.	O

Patients	O
unable	O
or	O
not	O
willing	O
to	O
return	O
for	O
follow	O
-	O
ups	O
.	O

Participants	O
must	O
present	O
a	O
diagnosis	O
of	O
osteoporosis	B
based	O
on	O
DXA	B
measurement	O
of	O
the	O
bone	B
mineral	I
density	I
at	O
the	O
femur	B
neck	I
and	O
/	O
or	O
total	B
hip	I
and	O
/	O
or	O
lumbar	B
spine	I
(	O
T	B
value	I
2	B
.	I
5	I
SD	I
or	I
more	I
below	I
the	I
young	I
female	I
adult	I
mean	I
)	O
within	O
the	O
past	B
24	I
months	I
.	O

Not	B
in	O
treatment	O
with	O
anti	B
-	I
resorptive	I
agents	I
(	O
like	O
bisphosphonates	B
and	O
denosumab	B
)	O
for	O
more	B
than	I
4	I
consecutive	I
years	I
,	I
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
medication	O
-	O
related	O
osteonecrosis	O
of	O
the	O
jaws	O
(	O
Lo	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

=	B
50	I
years	I
old	B
.	O

In	O
self	O
-	O
reported	O
menopause	B
,	O
defined	O
as	O
the	O
permanent	B
cessation	B
of	I
ovulation	I
,	O
for	O
at	B
least	I
one	I
year	I
(	O
Soules	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Edentulous	O
area	O
involving	O
a	O
maximum	O
of	O
two	O
teeth	O
(	O
wisdom	O
teeth	O
and	O
second	O
molars	O
are	O
excluded	O
)	O
and	O
presenting	O
at	O
least	O
one	O
neighbouring	O
tooth	O
(	O
e	O
.	O
g	O
.	O
gap	O
in	O
the	O
area	O
of	O
a	O
second	O
premolar	O
and	O
first	O
molar	O
,	O
with	O
first	O
premolar	O
in	O
place	O
)	O
.	O

Residual	B
alveolar	I
width	I
=	B
4	I
mm	I
(	O
Milinkovic	O
and	O
Cordaro	O
,	O
2014	O
)	O
,	O
residual	B
alveolar	I
height	I
>	B
8	I
mm	I
,	O
enough	O
inter	O
-	O
arch	O
space	O
for	O
a	O
crown	O
(	O
at	O
least	O
5	O
mm	O
)	O
and	O
a	O
minimum	O
distance	O
of	O
7	O
mm	O
from	O
the	O
adjacent	O
teeth	O
(	O
Shah	O
and	O
Lum	O
,	O
2008	O
)	O
.	O
The	O
width	O
and	O
height	O
will	O
be	O
confirmed	O
after	O
x	O
-	O
ray	O
examination	O
in	O
Visit	O
2	O
.	O

Possibility	O
to	O
restore	O
a	O
functional	O
occlusion	O
with	O
a	O
minimum	O
of	O
four	O
occlusal	O
units	O
(	O
i	O
.	O
e	O
.	O
pairs	O
of	O
occluding	O
posterior	O
teeth	O
)	O
.	O

Willingness	O
to	O
replace	O
the	O
missing	O
tooth	O
/	O
teeth	O
with	O
dental	O
implants	O

Registration	O
with	O
a	O
GDP	O

incooperative	B
for	O
glucose	B
monitor	I

refusal	B
of	O
insulin	B

pregnancy	B

Type	B
2	I
diabetic	I
inpatient	O

Fasting	B
glucose	I
>	B
140	I
mg	I
/	I
dl	I
or	O
random	B
glucose	I
>	B
180	I
mg	I
/	I
dl	I

Formal	O
indication	B
to	O
oral	B
anticoagulation	I
beside	O
atrial	B
fibrillation	I
(	O
mechanic	B
heart	I
valves	I
,	O
recurrent	B
thrombophlebitis	I
,	O
antiphospholipid	B
syndrome	I
)	O

Life	O
expectancy	O
<	B
6	I
months	I
(	O
e	O
.	O
g	O
.	O
,	O
terminal	B
cancer	I
)	O

Live	B
donor	I
transplantation	I
scheduled	O
within	B
6	I
months	I

Pregnancy	O
(	O
ß	O
-	O
HCG	O
blood	O
-	O
based	O
assay	O
)	O
or	O
nursing	O
(	O
lactating	O
)	O
women	O

Women	O
of	O
child	O
bearing	O
potential	O
,	O
unless	O
they	O
are	O
using	O
an	O
effective	O
method	O
of	O
birth	O
control	O

Patient	O
under	O
legal	O
guardianship	O

Patients	O
under	O
law	O
protection	O

Known	O
hypersensibility	B
to	O
coumadin	B
or	O
indoine	B
derivatives	O
or	O
to	O
any	O
excipients	O
(	O
CI	O
to	O
oral	O
AVK	O
)	O

Severe	B
liver	B
failure	I
(	O
CI	O
to	O
oral	O
AVK	O
)	O

Adult	B
patients	O
(	O
=	B
18	I
years	B
)	O

Patient	O
on	O
hemodialysis	B
treatment	O
for	O
at	B
least	I
1	I
month	I

Patient	O
with	O
a	O
history	O
of	O
,	O
or	O
presenting	O
a	O
new	B
episode	I
of	O
atrial	B
fibrillation	I
(	O
either	O
permanent	O
or	O
paroxysmal	O
)	O
.	O

Patient	O
with	O
a	O
CHADS2VASC	B
score	I
=	B
2	I

Patient	O
with	O
high	B
risk	O
of	O
bleeding	O
as	O
defined	O
by	O
(	O
1	O
)	O
HASBLED	B
score	I
=	B
3	I
OR	O
(	O
2	O
)	O
HASBLED	O
=	O
CHADS2VASC	B
score	I
,	O
OR	O
(	O
3	O
)	O
recent	O
history	O
of	O
severe	B
bleeding	I
(	O
type	B
3a	I
,	I
3b	I
,	I
3c	I
)	O
,	O
particularly	O
cerebral	B
or	O
gastrointestinal	B
,	O
OR	O
(	O
4	O
)	O
prior	O
recurrent	B
(	O
>	B
2	I
)	O
history	O
of	O
falls	O
.	O

Patient	O
capable	O
of	O
understanding	O
information	O
about	O
the	O
study	O
and	O
of	O
giving	O
his	O
/	O
her	O
consent	O

Patient	O
informed	O
of	O
the	O
preliminary	O
medical	O
exam	O
results	O

Patient	O
with	O
healthcare	O
insurance	O

Written	O
consent	O
signed	O

Subjects	O
who	O
have	O
systemic	B
infection	I

Subjects	O
who	O
have	O
human	B
Immunodeficiency	I
virus	I
(	I
HIV	I
)	I
,	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
,	O
and	O
hepatitis	B
C	I
virus	I
(	I
HCV	I
)	I

Subjects	O
who	O
need	O
to	O
take	O
the	O
medicine	O
which	O
is	O
prohibited	O
during	O
this	O
study	O

Subjects	O
who	O
have	O
asthma	B

Subjects	O
who	O
can	O
not	O
stop	O
treatment	O
with	O
topical	B
steroids	I
(	O
group	O
1	O
~	O
5	O
)	O
,	O
oral	B
antibiotics	I
,	O
whole	B
body	I
photochemotherapy	I
,	O
immunosuppressive	B
drug	I
within	B
4	I
weeks	I
before	I
the	O
treatment	O
visit	O

Pregnant	B
,	O
breast	B
-	I
feeding	I
women	B
or	O
women	B
who	O
plan	O
to	O
become	O
pregnant	B
during	B
this	I
study	I
(	O
Females	B
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
urine	B
pregnancy	I
test	I
)	O

Subjects	O
who	O
currently	O
participate	O
in	O
other	O
clinical	O
trial	O
or	O
participated	O
in	O
other	O
clinical	O
trial	O
within	O
30	O
days	O

Subjects	O
who	O
had	O
a	O
serious	B
adverse	I
events	I
during	B
stem	B
cell	I
therapy	I

Subjects	O
who	O
had	O
a	O
hypersensitivity	B
to	O
antibiotics	B
or	O
antimycotics	B

Subjects	O
who	O
creatinine	B
value	O
is	O
more	B
than	I
two	I
times	I
of	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
range	I
at	B
screening	I
test	I

Subjects	O
who	O
aspartate	B
transaminase	I
/	I
alkaline	I
transaminase	I
(	I
AST	I
/	I
ALT	I
)	I
value	O
is	O
more	B
than	I
three	I
times	I
of	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
range	I
at	B
screening	I
test	I

Subjects	O
who	O
have	O
any	B
other	I
condition	I
which	O
the	B
investigator	I
judges	I
would	I
make	I
patients	I
unsuitable	I
for	I
study	I
participation	I

Of	O
either	O
gender	O
,	O
aged	B
≥	B
19	I
and	I
≤	I
70	I
years	I

Atopic	B
dermatitis	I
subjects	O
who	O
are	O
coincident	O
with	O
Hanifin	B
and	I
Rajka	I
diagnosis	I
criteria	I

Subacute	B
and	O
chronic	B
atopic	O
subjects	O
who	O
have	O
atopic	O
dermatitis	B
symptoms	I
continually	B
at	I
least	I
6	I
months	I

Subjects	O
with	O
over	B
moderate	I
atopic	B
dermatitis	I
(	O
SCORAD	B
score	I
>	B
20	I
)	O

Subjects	O
who	O
understand	O
and	O
voluntarily	O
sign	O
an	O
informed	O
consent	O
form	O

Genotype	B
2	B
,	I
3	I
,	I
5	I
or	I
6	I
infection	B
.	O

Decompensated	B
cirrhosis	B
defined	O
by	O
the	O
presence	O
of	O
actual	B
or	O
previous	B
history	O
of	O
clinical	B
decompensation	I
including	O
ascites	B
,	O
hepatic	B
encephalopathy	I
,	O
variceal	B
bleeding	I
or	O
spontaneous	B
bacterial	I
peritonitis	I
,	O
or	O
a	O
Child	B
-	I
Pugh	I
B	B
or	I
C	I
.	O

Hepatocellular	B
carcinoma	I
after	O
liver	B
transplantation	I
.	O

Total	B
bilirubin	I
>	B
3	I
mg	I
/	I
dL	I
.	O

Immunosuppression	B
with	O
cyclosporine	B
or	O
an	O
mTOR	B
inhibitor	I
(	O
everolimus	B
or	O
sirolimus	B
)	O
.	O

Severe	B
extrahepatic	B
diseases	I
:	O
cardiovascular	B
,	O
respiratory	B
,	O
cerebrovascular	B
and	O
poorly	B
controlled	I
diabetes	B
.	O

Platelets	B
<	B
75	I
x	I
109	I
cells	I
/	I
L	I
.	O

Neutrophil	B
count	I
<	B
0	I
.	I
5	I
x	I
109	I
cells	I
/	I
L	I
.	O

Hemoglobin	B
<	B
9	I
g	I
/	I
dL	I
.	O

Albumin	B
<	B
3g	I
/	I
dL	I
.	O

HIV	B
infection	I
.	O

Hepatitis	B
B	I
infection	I
.	O

Active	B
intake	I
of	O
toxic	B
amounts	I
of	O
alcohol	B
or	O
recreational	B
drugs	I
.	O

Females	B
who	O
are	O
pregnant	B
,	O
become	O
to	O
be	O
pregnant	B
or	O
breastfeeding	O
or	O
males	B
whose	O
partners	O
are	O
pregnant	O
,	O
become	O
to	O
be	O
pregnant	O
or	O
breastfeeding	O
.	O

Intake	O
of	O
disallowed	B
medications	I
including	O
(	O
but	O
not	O
limited	O
to	O
)	O
:	O

1	O
.	O

Antibiotics	O
:	O
clarithromycin	B
,	O
erythromycin	B
,	O
telithromycin	B
,	O
nafcillin	B
,	O
rifampin	B

2	O
.	O

Antifungals	O
:	O
itraconazole	B
,	O
ketoconazole	B
,	O
voriconazole	B

3	O
.	O

Antihypertensives	O
:	O
nifedipine	B

4	O
.	O

Anticonvulsants	O
:	O
carbamazepine	B
,	O
phenytoin	B
,	O
phenobarbital	B

5	O
.	O

Bosentan	B

6	O
.	O

Modafinil	B

7	O
.	O

St	B
.	I
Jonh	I
'	I
s	I
Wort	I

8	O
.	O

Immunosuppressants	O
:	O
cyclosporin	B
,	O
everolimus	B
,	O
sirolimus	B

9	O
.	O

Diabetes	O
agents	O
:	O
glibenclamide	B
,	O
glyburide	B

10	O
.	O

Lipid	O
lowering	O
agents	O
:	O
gemfibrozil	B

11	O
.	O

Eltrombopag	B

12	O
.	O

Lapatinib	B

13	O
.	O

HIV	O
medications	O
:	O
efavirenz	B
,	O
etravirine	B
,	O
all	O
ritonavir	B
boosted	O
and	O
unboosted	O
HIV	B
protease	I
inhibitors	I

14	O
.	O

Statins	O
:	O
simvastatin	B
,	O
fluvastatin	B
,	O
rosuvastatin	B
at	O
doses	B
greater	I
than	I
10	I
mg	I
/	I
d	I
,	O
atorvastatin	B
at	O
doses	B
greater	I
than	I
10	I
mg	I
/	I
d	I
.	O

Age	B
between	B
18	I
and	I
78	I
year	I
-	I
old	I
.	O

Previous	B
liver	B
transplantation	I
(	O
more	B
than	I
6	I
month	I
)	O
.	O

Genotype	B
1	B
and	I
4	I
infection	B
.	O

Hepatitis	B
C	I
recurrence	B
defined	O
by	O
the	O
presence	O
of	O
abnormal	B
liver	B
function	I
test	I
,	O
positive	B
HCV	B
-	I
RNA	I
,	O
histological	B
signs	O
of	O
hepatitis	B
C	I
recurrence	B
.	O

Viral	B
load	I
≥	B
10000UI	I
/	I
mL	I
.	O

Immunosuppression	B
with	O
tacrolimus	B
and	O
/	O
or	O
mycophenolate	B
(	O
Prednisone	B
use	O
is	O
allowed	O
at	O
low	B
dose	I
,	O
≤	B
10	I
mg	I
/	I
d	I
)	O
.	O

Treatment	B
naïve	I
or	O
treatment	B
experienced	I
(	O
Peg	B
-	I
RBV	I
or	O
triple	B
therapy	I
)	O
.	O

ED	O
physicians	O
who	O
work	O
casually	O
(	O
less	O
than	O
0	O
.	O
25	O
Full	O
Time	O
Equivalent	O
)	O

ED	O
Physicians	O
who	O
are	O
routinely	O
using	O
U	O
/	O
S	O
guided	O
RA	O
for	O
hip	O
fracture	O
patients	O
,	O
or	O
decline	O
participation	O
in	O
the	O
trial	O
.	O

Patients	O
'	O
age	B
less	B
than	I
65	I
years	I
;	O

Patients	O
who	O
are	O
delirious	B
on	B
initial	I
assessment	I
by	O
ED	O
physician	O
or	O
severe	B
dementia	B

Patients	O
with	O
communication	B
problems	I
(	O
critically	B
ill	I
,	O
unconscious	B
,	O
language	B
barrier	I
despite	O
use	O
of	O
secure	O
telephone	O
-	O
based	O
translation	O
service	O
)	O

Patients	O
with	O
allergies	B
to	O
narcotics	B
or	O
local	B
anesthetic	I
;	O
or	O
anticoagulant	B
use	O
(	O
e	O
.	O
g	O
.	O
warfarin	B
,	O
dabigatran	B
,	O
rivaroxaban	B
)	O
.	O

Patients	O
with	O
hip	B
fractures	I
not	B
requiring	O
surgery	B
(	O
e	O
.	O
g	O
.	O
greater	B
trochanter	I
avulsion	I
)	O
will	O
also	O
be	O
excluded	O
.	O

At	O
the	O
cluster	O
level	O
,	O
ED	O
physicians	O
practicing	O
at	O
a	O
participating	O
site	O
will	O
be	O
eligible	O
.	O

At	O
the	O
patient	O
level	O
,	O
all	O
hip	B
fractures	I
seen	O
by	O
a	O
participating	O
ED	O
physician	O
will	O
be	O
eligible	O

Patient	O
refusal	O

Allergy	B
to	O
local	B
anaesthesia	I

Severe	B
coagulopathy	B

Contralateral	B
phrenic	B
nerve	I
palsy	I

Local	B
infection	I

Moderate	B
to	O
severe	B
pulmonary	B
dysfunction	I
(	O
GOLD	B
II	B
,	I
II	I
,	I
IV	I
)	O

Patients	O
undergoing	O
surgery	B
on	O
shoulder	B
,	O
humerus	B
,	O
or	O
clavicle	B

Contraindications	B
for	O
magnetic	B
resonance	I
imaging	I

Hemosiderosis	B
/	O
hemochromatosis	B
(	O
patients	O
can	O
still	O
be	O
included	O
in	O
the	O
non	O
-	O
ferumoxytol	O
arm	O
)	O

Osteonecrosis	B

planned	O
decompression	B
surgery	I
with	O
autologous	B
stem	I
cell	I
transplant	I

Bismuth	B
compounds	I
,	O
acid	B
inhibitor	I
,	O
or	O
antibiotics	B
during	B
4	I
weeks	I
before	I
the	I
patient	I
is	I
enrolled	I

Allergic	B
to	O
the	O
medications	B

Upper	B
gastrointestinal	I
surgery	I
history	B

Serious	B
heart	B
insufficiency	I
,	O
liver	B
insufficiency	I
,	O
renal	B
insufficiency	I
and	O
other	B
serious	B
medical	I
problems	I

Evidence	O
of	O
blood	B
dyscrasia	I

Pregnant	B
and	O
lactating	B
women	B

Can	O
'	O
t	O
express	O
his	O
complain	O
correctly	O
and	O
can	O
'	O
t	O
cooperate	O
with	O
the	O
researcher	O

A	O
positive	B
13	B
C	I
-	I
urea	I
breath	I
test	I

Formal	O
H	B
.	I
pylori	I
treatment	I
more	B
than	I
two	I
times	I

Age	B
>	B
18	I
years	I

Purulent	B
infection	I

Refusal	O
to	O
participate	O

Allergy	B
to	O
tested	B
material	I

Patients	O
after	O
throat	B
surgeries	I
:	O
tonsillectomy	B
,	O
adenotonsillectomy	B
,	O
uvulopalatoplasty	B
,	O
uvulopalatopharyngoplasty	B

Patients	O
with	O
acute	B
throat	I
diseases	I
:	O
pharyngitis	B
,	O
tonsillitis	B
,	O
pharyngotonsillitis	B

Age	B
less	B
than	I
one	I
year	I
or	O
age	B
greater	B
than	I
/	I
equals	I
to	I
18	I
years	I

Previous	B
treatment	B
with	O
cytotoxic	B
agents	I
or	O
high	B
-	I
dose	I
steroids	I

Mixed	B
phenotype	I
acute	I
leukemia	I
(	O
MPAL	B
)	O

ALL	B
as	O
secondary	B
malignancy	B

Abnormal	B
renal	I
or	I
liver	I
function	I

Doubtful	O
compliance	O
or	O
unable	O
to	O
afford	O
full	O
course	O
of	O
therapy	O

Confirmed	B
diagnosis	O
of	O
non	B
-	I
Burkitt	I
B	I
-	I
lineage	I
ALL	I

1	B
to	I
17	I
years	I
of	O
age	B
(	O
before	O
18th	O
birthday	O
)	O

Renal	B
function	I
within	B
normal	I
range	I
for	I
age	I

Liver	B
function	I
within	B
normal	I
range	I
for	I
age	I

Able	O
to	O
participate	O
in	O
the	O
full	B
2	I
years	I
of	O
treatment	B

Cardiac	B
arrest	I

Head	B
trauma	I

Drowning	B

Congenital	B
heart	I
disease	I

Inborn	B
errors	I
of	I
metabolism	I

Electrolyte	B
imbalance	I
(	O
hypocalcaemia	B
,	O
hyponatremia	B
and	O
hypoglycemia	B
)	O

Hemodynamic	B
instability	I

Allergy	B
to	O
benzodiazepines	B

Focal	B
seizures	I
with	O
preserved	B
level	I
of	I
consciousness	I

Children	B
6	O
month	O
to	O
14	O
years	B
who	O
will	O
be	O
presented	O
to	O
the	O
pediatric	O
emergency	O
or	O
attended	O
by	O
emergency	O
medical	O
service	O
who	O
have	O
active	B
seizure	B
and	O
had	O
no	B
intravenous	B
access	I
would	O
be	O
eligible	O
for	O
the	O
study	O
.	O

Overlap	B
syndrome	I
with	O
Primary	B
Sclerosing	I
Cholangitis	I
(	O
PSC	B
)	O
or	O
Primary	B
Biliary	I
Cholangitis	I
(	O
PBC	B
)	O
(	O
Paris	B
criteria	I
,	I
strong	B
positive	I
Anti	B
-	I
Mitochondrial	I
Antibodies	I
(	O
AMA	B
)	O
,	O
past	O
liver	B
biopsy	I
or	O
cholangiographic	B
findings	I
compatible	O
with	O
PBC	B
or	O
PSC	B
)	O
.	O

Presentation	O
with	O
acute	B
liver	I
failure	I
,	O
defined	O
as	O
presence	O
of	O
hepatic	B
encephalopathy	I
and	O
coagulopathy	B
(	O
INR	B
>	B
1	I
.	I
5	I
)	O

Current	O
treatment	O
with	O
prednisone	B
/	O
prednisolone	B
and	O
/	O
or	O
immunosuppressive	B
medication	I
for	O
an	O
indication	B
other	B
than	O
autoimmune	B
hepatitis	I

Current	O
systemic	B
infection	I

Other	O
clinically	O
significant	O
medical	O
conditions	O
that	O
could	O
interfere	O
with	O
the	O
trial	O

If	O
female	O
of	O
childbearing	O
potential	O
:	O
known	O
pregnancy	O
,	O
or	O
unwilling	O
to	O
practice	O
anticontraceptive	O
measures	O
.	O

History	O
of	O
noncompliance	O
with	O
medical	O
regimens	O
,	O
or	O
patients	O
who	O
are	O
considered	O
to	O
be	O
potentially	O
unreliable	O
or	O
unable	O
to	O
participate	O

Mental	O
instability	O
or	O
incompetence	O
,	O
such	O
that	O
the	O
validity	O
of	O
informed	O
consent	O
or	O
compliance	O
with	O
the	O
trial	O
is	O
uncertain	O

Probable	O
or	O
definite	O
diagnosis	O
of	O
autoimmune	B
hepatitis	I
according	O
to	O
the	O
International	B
Autoimmune	I
Hepatitis	I
Study	I
Group	I
criteria	I

First	O
presentation	O
of	O
AIH	B
requiring	O
treatment	B
according	O
to	O
the	O
current	O
EASL	B
guidelines	I

Age	B
=	B
18	I
years	I

Must	O
provide	O
informed	O
consent	O
and	O
agree	O
to	O
comply	O
with	O
the	O
trial	O
protocol	O

pregnant	O
or	O
breastfeeding	O
woman	O

patient	O
with	O
a	O
measure	O
of	O
legal	O
protection	O

subject	O
unaffiliated	O
insurance	O

patient	O
18	O
years	O
old	B
and	O
more	O

with	O
multiple	B
sclerosis	I
according	O
to	O
the	O
criteria	B
of	I
Mac	I
Donald	I
2010	I
:	O
relapsing	B
-	I
remitting	I
(	O
RR	B
)	O
,	O
secondary	B
-	I
progressive	I
(	O
SP	B
)	O
or	O
primary	B
-	I
progressive	I
(	O
PP	B
)	O

for	O
which	O
treatment	O
with	O
dimethyl	B
-	I
fumarate	I
has	O
been	O
prescribed	O

followed	O
at	O
the	O
Rothschild	O
Foundation	O
in	O
the	O
Neurology	O
Department	O

having	O
given	O
written	O
consent	O
to	O
participation	O
in	O
the	O
study	O

Documented	O
positive	B
hepatitis	B
B	I
(	I
HBV	I
)	I
surface	I
antigen	I
,	O
and	O
/	O
or	O
HBV	B
DNA	I
prior	B
to	I
enrollment	I

Any	O
prior	O
exposure	O
to	O
HCV	B
protease	I
inhibitor	I
therapy	I

HIV	B
co	I
-	I
infection	I
if	O
on	O
a	O
protease	B
inhibitor	I
based	O
regimen	O

Increase	O
in	O
creatinine	B
of	O
15	O
%	O
or	O
greater	O
within	B
one	I
month	I
(	O
30	B
days	I
)	O
of	O
the	O
screening	O
visit	O

Evidence	O
of	O
hepatocellular	B
carcinoma	I
at	O
the	O
time	O
of	O
enrollment	O

Liver	B
disease	I
caused	O
by	O
an	O
etiology	O
other	B
than	O
HCV	O

F4	O
or	O
decompensated	B
cirrhotic	I
patients	O

Child	B
Pugh	I
class	I
B	B
or	I
C	I

AST	B
or	O
ALT	B
>	B
350	I
within	B
6	I
months	I
prior	I
to	I
enrollment	I

Albumin	B
<	B
3g	I
/	I
dL	I
at	O
the	O
time	O
of	O
enrollment	O

Platelet	B
count	I
<	B
75	I
at	O
the	O
time	O
of	O
enrollment	O

History	O
of	O
clinically	O
significant	O
allergy	B
or	O
adverse	B
event	I
with	O
protease	B
inhibitors	I

Evidence	O
of	O
the	O
acquisition	B
of	I
HCV	I
at	B
the	I
time	I
of	I
or	I
after	I
transplantation	I

Pregnant	O
or	O
breastfeeding	O
women	O

Cyclosporine	B
;	O
St	B
.	I
John	I
'	I
s	I
Wort	I
;	O
Efavirenz	B
;	O
Phenytoin	B
;	O
Carbamazepine	B
;	O
Bosentan	B
;	O
HIV	B
protease	I
inhibitors	I
;	O
modafinil	B
;	O
ketoconazole	B
;	O
or	O
rifampin	B
use	O
within	B
7	I
days	I
of	I
enrollment	I

Coadministration	O
of	O
more	B
than	I
20	I
mg	I
atorvastatin	B
;	O
10	O
mg	O
rosuvastatin	B
;	O
20	O
mg	O
of	O
fluvastatin	B
,	O
lovastatin	B
or	O
simvastatin	B

At	B
least	I
18	I
years	I
of	O
age	B
at	O
the	O
time	O
of	O
screening	O

Have	O
stable	B
renal	B
function	I
for	O
one	B
month	I
(	I
30	I
days	I
)	I
prior	I
to	I
enrollment	I

Have	O
Chronic	B
HCV	I
infection	I
prior	B
to	I
transplantation	I
with	O
documented	O
HCV	B
viremia	I
=	B
1	I
,	I
000	I
IU	I
/	I
ml	I
at	O
screening	O
and	O
either	O
documented	O
HCV	B
Ab	I
positivity	B
or	O
HCV	B
viremia	I
=	B
1	I
,	I
000	I
IU	I
/	I
ml	I
at	B
least	I
6	I
months	I
prior	I
to	I
enrollment	I
.	I

Documented	O
genotype	B
1	I
HCV	B
infection	I
prior	B
to	I
enrollment	I
and	O
after	B
their	I
transplant	I
in	I
the	O
post	O
-	O
transplantation	O
cohort	O

HCV	B
disease	B
staging	I
within	B
12	I
months	I
prior	I
to	I
enrollment	I
by	O
liver	B
biopsy	I
,	O
transient	B
elastography	I
,	O
or	O
biochemical	B
testing	I

Be	O
able	O
to	O
give	O
informed	O
consent	O
and	O
comply	O
with	O
study	O
guidelines	O

Women	O
of	O
childbearing	O
age	O
will	O
be	O
required	O
to	O
have	O
a	O
negative	O
pregnancy	O
test	O
at	O
enrollment	O
and	O
use	O
birth	O
control	O
throughout	O
the	O
duration	O
of	O
treatment	O
.	O

On	O
the	O
transplant	O
waiting	O
list	O
followed	O
by	O
the	O
University	O
of	O
Maryland	O
'	O
s	O
nephrology	O
clinic	O
or	O
the	O
Baltimore	O
VA	O
'	O
s	O
nephrology	O
clinic	O

On	O
chronic	B
hemodialysis	B
not	O
yet	O
on	O
the	O
transplant	O
list	O
and	O
followed	O
in	O
the	O
University	O
'	O
s	O
hemodialysis	O
center	O
or	O
in	O
the	O
University	O
'	O
s	O
nephrology	O
clinic	O

Have	O
chronic	B
kidney	I
disease	I
with	O
GFR	B
<	B
50	I

Exclusion	O
criteria	O
include	O
patients	O
following	O
resuscitation	B
from	I
cardiac	I
arrest	I
who	O
are	O
treated	O
on	O
the	O
cooling	B
protocol	I

patients	O
who	O
have	O
suffered	O
a	O
neurologic	B
event	I
(	O
seizure	B
,	O
stroke	B
)	O
or	O
who	O
have	O
baseline	B
dementia	I
,	O
both	O
of	O
which	O
could	O
limit	O
delirium	O
assessment	O

patients	O
with	O
child	B
class	I
B	B
and	O
C	B
liver	B
disease	I

patients	O
with	O
known	O
allergy	B
to	O
study	B
medications	I
.	O

All	O
patients	O
admitted	B
to	O
the	O
Duke	O
CICU	O
,	O
who	O
require	O
intubation	B
and	O
sedation	B
for	O
mechanical	B
ventilation	I
that	O
is	O
expected	O
to	O
be	O
>	B
24	I
hours	I
in	I
duration	I
will	O
be	O
included	O
,	O
unless	O
they	O
meet	O
the	O
specified	O
exclusion	O
criteria	O
.	O

Patients	O
intubated	B
within	O
one	O
hour	O
prior	O
to	O
care	B
transition	I
to	O
the	O
CICU	O
will	O
also	O
be	O
screened	O
for	O
inclusion	O
.	O

History	B
of	O
spinal	B
cord	I
stenosis	I
or	O
clinical	B
symptoms	I
of	O
lumbar	B
radiculopathy	I
;	O

History	B
or	O
onset	B
neurological	B
diseases	I
;	O

Generalized	B
pain	I
or	O
fibromyalgia	B
;	O

Inability	B
to	I
walk	I
;	O

History	B
of	O
knee	B
surgery	I
in	O
the	O
target	O
knee	O
;	O

Secondary	B
causes	I
of	O
osteoarthritis	B
;	O

Use	O
of	O
statins	B
and	O
quinolones	B
in	B
the	I
previous	I
year	I
;	O

Uncontrolled	B
and	O
ongoing	B
psychiatric	B
diseases	I
;	O

Invasive	B
knee	I
treatments	I
with	O
hyaluronic	B
acid	I
infusion	O
,	O
corticosteroids	B
and	O
anaesthetics	B
,	O
in	O
the	O
target	O
knee	O
,	O
up	B
to	I
6	I
months	I
previous	I
to	O
study	O
inclusion	O
.	O

Clinical	O
and	O
radiologic	B
diagnosis	I
of	O
primary	B
knee	I
osteoarthritis	I
(	O
Kellgren	B
&	I
Lawrence	I
I	B
,	I
II	I
or	I
III	I
)	O
;	O

Capability	O
to	O
understand	O
the	O
Informed	O
Consent	O
Form	O
;	O

Chronic	B
pain	I
for	O
at	B
least	I
3	I
months	I
prior	I
to	O
inclusion	O
,	O
measured	O
by	O
VAS	B
.	O

(	O
VAS	B
4	B
or	I
above	I
)	O
;	O

Absence	B
of	O
skin	B
injures	I
,	O
infections	B
or	O
tumor	B
in	O
the	O
target	O
knee	O
;	O

Availability	O
to	O
comply	O
with	O
the	O
visits	O
.	O

Lack	O
of	O
understanding	O
of	O
the	O
study	O

contra	B
-	I
indication	I
to	O
nicotine	B
replacement	I
therapy	I

health	O
status	O
incompatible	O
with	O
detention	O
in	O
police	O
cells	O

serious	B
mental	I
disorder	I

usual	O
place	O
of	O
residence	O
outside	B
Seine	I
-	I
Saint	I
-	I
Denis	I

Arrestees	B
examined	B
by	I
a	I
physician	I
during	B
detention	I
in	I
police	I
cells	I

aged	B
18	B
or	I
older	I

smoking	O
at	B
least	I
10	I
cigarettes	I
per	I
day	I

giving	O
written	O
consent	O
to	O
participate	O
in	O
the	O
study	O

health	B
status	I
compatible	B
with	I
detention	I
in	I
police	I
cells	I

Currently	O
pregnant	O
or	O
using	O
a	O
reliable	O
contraception	O
(	O
e	O
.	O
g	O
.	O
injectables	O
,	O
intrauterine	O
devices	O
,	O
implant	O
,	O
oral	O
contraceptive	O
pills	O
)	O

Desiring	O
pregnancy	O
in	O
the	O
next	O
year	O

History	O
of	O
tubal	B
ligation	I
or	O
hysterectomy	B

Contraindication	O
to	O
progestin	B
-	O
only	B
contraceptives	B

Unable	O
to	O
comprehend	O
consent	O
material	O
because	O
of	O
language	O
barrier	O
or	O
psychological	O
difficulty	O

BV	B
positive	B
by	O
Nugent	B
score	I

HIV	B
negative	B

Capable	O
of	O
providing	O
written	O
informed	O
consent	O

Contra	B
-	I
indication	I
for	O
multiorgan	B
procurement	I
(	O
infections	B
,	O
cancer	B
,	O
etc	O
)	O

Preexistent	B
chronic	B
renal	I
failure	I
.	O

Refusal	O
for	O
organ	B
procurement	I
by	O
the	O
donor	O
(	O
confirmed	O
by	O
the	O
French	B
national	I
register	I
or	O
reported	B
by	I
the	I
next	I
-	I
of	I
-	I
kin	I
)	O
.	O

Need	O
for	O
a	O
double	B
kidney	I
transplantation	I
.	O

Need	O
for	O
a	O
multiorgan	B
transplantation	I

Male	B
and	O
females	B
aged	B
18	B
to	I
70	I
years	I

Brain	B
death	I

Male	B
and	O
females	B
aged	B
18	B
to	I
70	I
years	I

Indication	O
of	O
kidney	B
transplantation	I

Informed	O
consent	O

ileus	B

known	O
or	O
suspected	O
bowel	B
obstruction	I

active	B
bowel	B
inflammation	I

pregnancy	B

any	O
presence	O
of	O
serious	B
medical	I
conditions	I
(	O
esp	O
.	O
cardiac	O
,	O
renal	O
,	O
liver	B
diseases	I
)	O

history	B
of	I
prior	B
colonic	O
or	O
rectal	B
surgery	I

inability	O
to	O
obtain	O
valid	O
data	O
from	O

Subjects	O
referred	O
to	O
diagnostic	O
or	O
therapeutic	O
colonoscopy	B
.	O

tinnitus	B
or	O
hearing	B
loss	I
with	O
same	O
debut	O
as	O
vertigo	B

history	O
of	O
bleeding	B
peptic	B
ulcer	I

glaucoma	B

pregnancy	O
or	O
non	O
-	O
acceptance	O
to	O
use	O
anticonception	O
measures	O
during	O
13	O
days	O
after	O
debut	O

high	O
blood	O
pressure	O
>	B
180	I
systolic	O
,	O
105	B
,	O
diastolic	O

ketoacidosis	B
with	O
a	O
Base	B
Excess	I
>	B
=	I
2	I

psychic	B
disorder	I
(	O
not	B
including	O
mild	B
depression	I
)	O

serious	B
infection	B
(	O
neutropenia	B
,	O
tuberculosis	B
)	O

chronic	B
otitis	I

history	O
of	O
vertiginous	B
disease	I
;	O
Ménière	B
,	O
Vertiginous	B
migraine	I
,	O
atypical	B
BPPV	I

definite	O
unilateral	B
vestibulopathy	B

no	B
pathological	B
HINTS	B
(	O
examination	O
criteria	O
in	O
acute	B
vestibular	I
syndrome	I
)	O

capable	O
of	O
making	O
their	O
own	O
decisions	O

indication	O
for	O
catheter	B
insertion	I
;	O

contraindications	B
to	O
brachial	B
plexus	I
block	I
(	O
e	O
.	O
g	O
.	O
,	O
allergy	B
to	O
local	B
anaesthetics	I
,	O
malignancy	B
or	O
infection	B
in	B
the	I
area	I
)	O
;	O

existing	B
neurological	B
deficit	I
in	O
the	O
area	B
to	I
be	I
blocked	I
;	O

pregnancy	B
;	O

history	B
of	O
neck	B
surgery	I
or	O
radiotherapy	B
;	O

severe	B
respiratory	B
disease	I
;	O

chest	B
deformity	I
;	O

inability	O
to	O
understand	O
the	O
informed	O
consent	O
and	O
demands	O
of	O
the	O
study	O
;	O

patient	O
refusal	O
.	O

ASA	B
physical	I
status	I
I	B
-	I
III	I
;	O

18	O
-	O
85	O
years	O
of	O
age	B
,	O
inclusive	O
;	O

surgery	B
less	B
than	I
3	I
hours	I
.	O

NA	O

Male	B
or	O
female	B
=	B
18	I
years	I
of	O
age	B
at	B
Visit	I
1	I
.	I

Sweat	B
chloride	I
equal	B
or	I
greater	I
than	I
60	I
mEq	I
/	I
L	I
by	O
quantitative	B
pilocarpine	I
iontophoresis	I
test	I
.	O

Two	B
well	O
-	O
characterized	O
mutations	B
in	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	B
)	O
gene	O

Abnormal	B
nasal	B
potential	I
difference	I
(	O
NPD	B
)	O
as	O
measured	O
by	O
a	O
change	O
in	O
NPD	O
in	O
response	O
to	O
a	O
low	O
chloride	O
solution	O
and	O
isoproterenol	O
of	O
less	B
than	I
-	I
5	I
mV	I
.	O

Documentation	O
of	O
the	O
presence	O
of	O
an	O
acute	B
pulmonary	I
exacerbation	I
,	O
based	O
on	O
CF	B
Foundation	I
guidelines	I
,	O
as	O
diagnosed	O
by	O
a	O
faculty	O
member	O
of	O
the	O
Denver	O
Adult	O
CF	O
Program	O
.	O

Respiratory	B
culture	I
(	I
s	I
)	I
demonstrating	O
evidence	O
of	O
Pseudomonas	B
aeruginosa	I
or	O
Achromobacter	B
species	I
airway	B
infection	I
.	O

Subject	O
is	O
able	O
to	O
produce	O
sputum	O
,	O
undergo	O
phlebotomy	O
,	O
and	O
provide	O
written	O
consent	O
.	O

The	O
subject	O
'	O
s	O
treating	O
physician	O
has	O
determined	O
that	O
they	O
should	O
receive	O
either	O
tobramycin	O
or	O
colistin	O
intravenously	O
as	O
one	O
of	O
the	O
designated	O
agents	O
for	O
their	O
APE	O
treatment	O
.	O
Subjects	O
who	O
are	O
able	O
to	O
receive	O
either	O
tobramycin	O
or	O
colistin	O
as	O
part	O
of	O
their	O
antibiotic	O
regimen	O
will	O
be	O
randomized	O
into	O
one	O
of	O
three	O
arms	O
.	O
If	O
a	O
treating	O
physician	O
deems	O
that	O
a	O
subject	O
cannot	O
receive	O
tobramycin	O
due	O
to	O
vestibular	O
toxicity	O
,	O
ototoxicity	O
or	O
bacterial	O
resistance	O
,	O
the	O
subject	O
will	O
be	O
randomized	O
to	O
either	O
standard	O
or	O
PK	O
-	O
adjusted	O
colistin	O
.	O

Any	O
significant	O
acute	B
or	O
chronic	B
medical	B
illness	I
or	O
problem	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
diabetes	B
,	O
hypertension	B
,	O
cardiac	B
disease	I
,	O
asthma	B
,	O
chronic	B
obstructive	I
lung	I
disease	I

Current	O
or	O
recent	O
(	O
last	B
60	I
days	I
)	O
tobacco	O
or	O
nicotine	O
use	O

History	O
of	O
sickle	B
cell	I
trait	I
or	O
disease	O
or	O
any	O
other	O
acquired	O
or	O
hereditary	B
hematological	I
abnormality	I

History	O
of	O
fainting	B
or	O
other	O
significant	O
adverse	B
reaction	I
during	O
phlebotomy	B
or	O
donation	O
of	O
blood	O

Known	O
prolonged	O
QTc	B
(	O
or	O
evidence	O
of	O
such	O
at	O
screening	O
)	O
on	O
electrocardiogram	B
defined	O
as	O
>	B
470	I
ms	I

Known	O
or	O
suspected	O
illicit	O
drug	O
or	O
alcohol	B
abuse	I

Known	O
or	O
suspected	O
HIV	O
,	O
Hepatitis	O
B	O
,	O
or	O
Hepatitis	B
C	I
infection	I

History	O
of	O
thrombophilia	B
or	O
anticoagulant	B
therapy	I

Pregnancy	B

Obesity	B
defined	O
as	O
BMI	B
>	B
30	I

Recent	O
history	O
of	O
blood	O
donation	O
:	O
a	O
)	O
Single	O
whole	O
blood	O
unit	O
donation	O
within	O
the	O
past	O
8	O
weeks	O
;	O
b	O
)	O
Double	O
RBC	O
donation	O
by	O
apheresis	O
within	O
the	O
past	O
16	O
weeks	O
;	O
or	O
c	O
)	O
Plasma	O
donation	O
by	O
apheresis	O
within	O
the	O
past	O
4	O
weeks	O

Inadequate	B
RBC	O
mass	O
based	O
on	O
TBV	B
<	B
4500	I
ml	I
(	O
above	O
)	O
or	O
screening	O
Hb	B
<	B
14	I
g	I
/	I
dL	I

Habitual	O
exerciser	O
defined	O
as	O
=	O
30	O
minutes	O
of	O
at	O
least	O
moderate	O
or	O
high	O
intensity	O
exercise	O
=	O
3	O
times	O
per	O
week	O
.	O
After	O
consent	O
,	O
and	O
at	O
the	O
subsequent	O
screening	O
visit	O
,	O
a	O
VO2	O
max	O
test	O
will	O
be	O
performed	O
,	O
and	O
subjects	O
with	O
a	O
low	O
value	O
(	O
<	O
35	O
mL	O
/	O
kg	O
/	O
min	O
)	O
will	O
be	O
excluded	O
(	O
screen	O
failure	O
)	O
.	O
Based	O
on	O
our	O
previous	O
experience	O
,	O
we	O
anticipate	O
that	O
<	O
10	O
%	O
of	O
the	O
subjects	O
will	O
fall	O
into	O
this	O
category	O

Men	B
:	O
(	B
0	I
.	I
006012	I
x	I
H3	I
)	I
+	I
(	I
14	I
.	I
6	I
x	I
W	I
)	I
+	I
604	I
=	I
TBV	B

Women	B
:	O
(	B
0	I
.	I
005835	I
x	I
H3	I
)	I
+	I
(	I
15	I
x	I
W	I
)	I
+	I
183	I
=	O
TBV	B
[	O
H	O
=	O
height	O
in	O
inches	O
;	O
W	O
=	O
weight	O
in	O
pounds	O
]	O

Has	O
access	O
to	O
transportation	O
to	O
visit	O
the	O
blood	O
collection	O
facility	O
and	O
to	O
return	O
to	O
Stony	O
Brook	O
for	O
all	O
study	O
visits	O
.	O

Established	O
Osteoarthritis	B
(	O
Kellgren	B
-	I
Lawrence	I
>	B
3	I
)	O

Minimum	B
joint	I
space	I
>	B
2	I
mm	I
as	O
measured	O
on	O
AP	B
radiograph	I

Hip	B
dysplasia	I
(	O
center	B
edge	I
angle	I
<	B
20	I
°	I
on	O
AP	B
radiograph	I
)	O

Patients	O
with	O
clinically	O
significant	B
cardiovascular	O
,	O
renal	O
,	O
hepatic	O
,	O
endocrine	B
disease	I
,	O
cancer	B
or	O
diabetes	B

Patients	O
with	O
ongoing	B
infection	B
including	O
HIV	B
and	O
Hepatitis	B

Patient	O
with	O
history	O
of	O
osteomyelitis	B
/	O
septic	B
arthritis	I

Anticoagulation	B
therapy	I

Patients	O
who	O
are	O
pregnant	O
or	O
breast	O
feeding	O

Patients	O
with	O
systemic	O
,	O
rheumatic	O
or	O
inflammatory	B
disease	I
of	O
the	O
knee	B
or	O
chondrocalcinosis	B
,	O
hemochromatosis	B
,	O
inflammatory	B
arthritis	I
,	O
arthropathy	B
of	I
the	I
knee	I
associated	O
with	O
juxta	B
-	I
articular	I
Paget	B
'	I
s	I
disease	I
of	O
the	O
femur	B
or	O
tibia	B
,	O
hemophilic	B
arthropathy	I
,	O
infectious	B
arthritis	I
,	O
Charcot	B
'	I
s	I
knee	I
joint	I
,	O
villonodular	B
synovitis	I
,	O
and	O
synovial	B
chondromatosis	I

Patients	O
taking	O
immunosuppressant	B
medication	I

Patients	O
with	O
abnormal	B
hematology	O
or	O
serum	B
chemistry	I
lab	I
results	O

Patients	O
receiving	O
injection	B
to	O
treatment	O
knee	B
within	B
2	I
months	I
of	I
study	I
enrollment	I

BMI	B
greater	B
than	I
35	I
or	O
less	B
than	I
20	I

Patients	O
with	O
symptomatic	B
FAI	B

Clinical	O
and	O
radiographic	B
evidence	I
of	O
FAI	B

Patients	O
able	O
to	O
provide	O
consent	O
to	O
study	O
participation	O

Completion	O
of	O
6	B
weeks	I
of	O
physical	B
therapy	I
program	I

age	B
>	B
80	I
years	I
;	O

Kellgren	B
-	I
Lawrence	I
score	I
at	O
X	B
-	I
ray	I
evaluation	I
>	B
3	I
;	O

major	B
axial	I
deviation	I
(	O
varus	B
>	B
5	I
°	I
,	O
valgus	B
>	B
5	I
°	I
)	O
,	O

systemic	B
disorders	I
such	O
as	O
diabetes	B
,	O
rheumatoid	B
arthritis	I
,	O
haematological	B
diseases	I
(	O
coagulopathy	B
)	O
,	O
severe	B
cardiovascular	B
diseases	I
,	O
infections	B
,	O
immunodepression	B
;	O

patients	O
in	O
therapy	B
with	O
anticoagulants	B
or	O
antiaggregants	B
;	O

use	O
of	O
NSAIDs	B
in	B
the	I
5	I
days	I
before	I
blood	I
donation	I
;	O

patients	O
with	O
Hb	B
values	O
<	B
11	I
g	I
/	I
dl	I
and	O
platelet	B
values	O
<	B
150	I
,	I
000	I
/	I
mmc	I
.	O

patients	O
affected	O
by	O
mono	B
-	I
lateral	I
symptomatic	B
knee	B
articular	I
degenerative	I
pathology	I
with	O
history	O
of	O
chronic	B
(	O
for	B
at	I
least	I
4	I
months	I
)	O
pain	B
or	O
swelling	B
;	O

imaging	B
findings	O
of	O
degenerative	B
changes	I
of	O
the	O
joint	O
(	O
osteoarthritis	B
or	O
chondropathy	B
with	O
Kellgren	B
Lawrence	I
Score	I
from	B
0	I
to	I
3	I
at	O
X	B
-	I
ray	I
evaluation	O
)	O
.	O

Relative	B
contraindications	I
to	O
ECT	B
therapy	I
(	O
recent	B
MI	B
or	O
CVA	B
,	O
increased	B
intracranial	B
pressure	I
,	O
intracranial	B
mass	I
lesion	I
,	O
intracranial	B
aneurysm	I
,	O
epilepsy	B
,	O
known	O
cardiac	B
arrhythmia	I
,	O
pheochromocytoma	B
,	O
pregnancy	B
)	O

Contraindications	B
to	O
etomidate	B
(	O
sepsis	B
,	O
primary	B
or	O
secondary	B
adrenal	B
insufficiency	I
,	O
porphyria	B
)	O

DSM	B
-	I
V	I
diagnosis	O
of	O
a	O
lifetime	B
history	I
of	O
psychotic	B
spectrum	I
disorder	I

Drug	O
or	O
alcohol	B
dependence	I
,	O
or	O
abuse	O
within	B
the	I
past	I
3	I
months	I
,	O
soy	B
-	I
bean	I
oil	I
allergy	I

Adults	B
patients	O
aged	B
18	B
to	I
85	I
years	I

Diagnosed	O
with	O
Major	B
Depressive	I
Disorder	I
,	O
unipolar	O
or	O
bipolar	B
depression	I

Undergoing	B
ECT	B
for	O
treatment	O
of	O
their	O
symptoms	O

Currently	O
residing	O
in	O
Manitoba	O

osteoarticular	O
,	O
neuromuscular	O
or	O
cognitive	O
limitation	O
that	O
prevents	B
ambulation	O

previous	O
diagnosis	O
of	O
active	O
neoplastic	B
disease	I

institutionalized	B
patients	O
;	O
alcohol	O
consumption	O
>	B
60	I
g	I
/	I
day	I

patient	O
belonging	O
to	O
another	O
health	O
sector	O
in	O
the	O
Community	O
of	O
Madrid	O
or	O
other	O
community	O

participation	O
in	O
another	O
study	O
within	O
6	O
months	O
prior	O
.	O

subjects	O
older	B
than	I
35	I
years	B

diagnosis	O
of	O
moderate	B
to	O
very	B
severe	I
COPD	B
(	O
FEV1	B
<	B
80	I
%	I
predicted	I
)	O
,	O
according	O
to	O
the	O
GesEPOC	B
criteria	I
,	I
established	O
at	B
least	I
3	I
months	I

current	O
or	O
former	O
smoker	B
with	O
an	O
accumulated	O
consumption	O
>	B
10	I
packs	I
x	I
year	I

hospital	O
admission	O
for	O
COPD	B
exacerbation	I

All	O
patients	O
who	O
were	O
wheelchair	O
bound	O
preoperatively	B

All	O
patients	O
who	O
cannot	B
participate	O
in	O
an	O
outpatient	O
physical	B
therapy	I
program	O
for	B
3	I
days	I
per	I
week	I
after	I
surgery	I

All	O
patients	O
will	O
be	O
undergoing	O
a	O
primary	B
unilateral	B
total	I
knee	I
arthroplasty	I
for	O
a	O
diagnosis	O
of	O
osteoarthritis	B

An	O
initial	B
plasma	B
sodium	I
concentration	I
of	O
lower	B
than	I
130	I
mmol	I
/	I
L	I

An	O
initial	B
plasma	B
sodium	I
concentration	I
of	O
higher	B
than	I
150	I
mmol	I
/	I
L	I

An	O
initial	B
plasma	B
potassium	I
concentration	I
of	O
lower	B
than	I
3	I
.	I
0	I
mmol	I
/	I
L	I

Need	O
for	O
10	B
%	I
glucose	I
solution	I

Diabetes	B

Diabetes	B
insipidus	I

Diabetic	B
ketoacidosis	I

Renal	B
disease	I
that	O
needs	O
dialysis	B

Protocol	B
-	I
determined	I
chemotherapy	B
hydration	I

Severe	B
liver	B
disease	I

Inborn	B
errors	I
of	I
metabolism	I
that	O
need	O
protocol	B
-	I
determined	I
fluid	B
therapy	I

Acutely	B
ill	I
hospitalised	O
children	B

Need	O
for	O
intravenous	B
fluid	I
therapy	I

ASA	B
4	B
or	I
5	I

revision	B
hip	I
arthroplasty	I

diagnosis	O
of	O
chronic	B
pain	I

daily	O
chronic	B
opioid	B
use	O
(	O
over	B
3	I
months	I
of	O
continuous	O
opioid	O
use	O
)	O

inability	O
to	O
communicate	O
pain	O
scores	O
or	O
need	O
for	O
analgesia	O

acute	B
hip	B
fracture	I

Infection	B
at	O
the	O
site	B
of	I
block	I
placement	I

Age	B
under	B
18	I
years	I
old	I
or	I
greater	I
than	I
75	I
years	I
old	I

Pregnant	O
women	O

Intolerance	B
/	O
allergy	B
to	O
local	B
anesthetics	I

Weight	B
<	B
50	I
kg	I

Suspected	O
,	O
or	O
known	O
addiction	B
to	O
or	O
abuse	B
of	O
illicit	B
drug	I
(	O
s	O
)	O
,	O
prescription	B
medicine	I
(	O
s	O
)	O
,	O
or	O
alcohol	B
within	O
the	O
past	B
2	I
years	I
.	O

Uncontrolled	O
anxiety	B
,	O
schizophrenia	B
,	O
or	O
other	O
psychiatric	B
disorder	I
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
may	O
interfere	O
with	O
study	O
assessments	O
or	O
compliance	O

Current	O
or	O
historical	O
evidence	O
of	O
any	O
clinically	O
significant	O
disease	O
or	O
condition	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
may	O
increase	O
the	O
risk	O
of	O
surgery	O
or	O
complicate	O
the	O
subject	O
'	O
s	O
postoperative	O
course	O
.	O

English	O
speaking	O

between	B
18	I
and	I
75	I
years	I
old	B

American	B
Society	I
of	I
Anesthesiologists	I
(	O
ASA	B
)	O
1	B
-	I
3	I
patients	O
undergoing	O
primary	B
total	I
hip	I
arthroplasty	I

Exposure	O
/	O
treatment	O
to	O
an	O
investigational	O
(	O
new	O
chemical	O
entity	O
)	O
or	O
marketed	O
drug	O
or	O
biologic	O
within	O
30	O
days	O
preceding	O
the	O
first	O
dose	O
administration	O
,	O
or	O
five	O
half	O
-	O
lives	O
of	O
that	O
investigational	O
drug	O
or	O
biologic	O
,	O
if	O
known	O
(	O
whichever	O
is	O
longer	O
)	O
.	O

Donation	B
blood	I
or	O
serum	O
within	B
8	I
weeks	I
before	I
the	O
first	O
dose	O
administration	O
to	O
a	O
blood	O
bank	O
or	O
blood	O
donation	O
center	O
.	O

History	B
of	O
alcohol	O
or	O
drug	B
abuse	I
(	O
as	O
defined	O
by	O
the	O
current	B
version	I
of	I
the	I
DSM	I
)	O
within	B
2	I
years	I
before	I
the	O
first	O
dose	O
administration	O
,	O
or	O
positive	B
alcohol	O
or	O
drug	B
screen	I
.	O

Vaccination	B
within	B
30	I
days	I
prior	I
to	O
the	O
first	O
dose	O
administration	O
or	O
has	O
plans	O
to	O
receive	O
a	O
vaccination	B
during	B
the	I
course	I
of	O
the	O
study	O
(	O
including	O
the	O
follow	O
phone	O
call	O
on	O
Day	O
105	O
)	O
.	O

Healthy	B
male	B
and	O
/	O
or	O
female	B
subjects	O
between	O
the	O
ages	B
of	O
18	O
and	O
55	O
years	O
,	O
and	O
a	O
body	B
mass	I
index	I
(	I
BMI	I
)	I
of	O
≥	B
18	I
and	I
≤	I
33	I
kg	I
/	I
m2	I
with	O
body	B
weight	I
≥	B
50	I
and	I
≤	I
90	I
kg	I
at	B
screening	I
.	O

Females	B
must	O
have	O
been	O
surgically	B
sterilized	I
(	O
hysterectomy	B
,	O
bilateral	B
oophorectomy	I
,	O
or	O
bilateral	B
salpingo	I
-	I
oophorectomy	I
;	O
proper	O
documentation	O
required	O
)	O
at	B
least	I
6	I
months	I
before	I
screening	O
,	O
or	O
be	O
postmenopausal	B
(	O
defined	O
as	O
24	B
consecutive	I
months	I
without	B
menses	B
before	B
screening	I
,	O
with	O
a	O
follicle	B
-	I
stimulating	I
hormone	I
[	I
FSH	I
]	I
level	O
of	O
>	B
40	I
IU	I
/	I
L	I
at	B
screening	I
)	O
.	O

patients	O
with	O
cancer	B

patients	O
with	O
chronic	B
inflammation	I
diseases	I

non	B
-	I
valvular	I
atrial	B
fibrillation	I

nondiabetic	B
patients	O

type	B
1	I
and	O
2	O
diabetic	B
patients	O

Women	O
refusing	B
HBs	B
Ag	I
test	I

HIV	B
co	B
-	I
infection	I

HCV	B
co	B
-	I
infection	I

HBV	B
treatment	I
ongoing	O
at	O
the	O
day	O
of	O
inclusion	O

Creatinine	B
clearance	I
<	B
30	I
mL	I
/	I
min	I

Severe	B
gravidic	B
disease	I
present	O
at	O
inclusion	O
involving	O
life	B
threatening	I
to	O
the	O
mother	O
and	O
/	O
or	O
the	O
child	O

Evidence	O
of	O
pre	O
-	O
existing	O
fetal	B
anomalies	I
incompatible	O
with	O
the	O
child	O
'	O
s	O
life	O

Imminent	B
child	I
'	I
s	I
birth	I
defined	O
as	O
cervix	B
dilatation	I
up	O
to	O
7	B
centimeters	I

Intention	O
to	O
deliver	O
in	O
a	O
maternity	O
not	O
linked	O
to	O
the	O
study	O

Any	O
concomitant	O
medical	O
condition	O
that	O
,	O
according	O
to	O
the	O
clinical	O
site	O
investigator	O
would	O
contraindicate	O
participation	O
in	O
the	O
study	O
.	O

Concurrent	O
participation	O
in	O
any	O
other	O
clinical	O
trial	O
without	O
written	O
agreement	O
of	O
the	O
two	O
study	O
teams	O

>	B
=	I
18	I
years	I
old	B
the	O
day	O
of	O
inclusion	O

Pregnancy	B

Positive	B
HBs	B
Ag	I

Informed	O
consent	O
obtained	O
with	O
information	O
sheet	O
given	O
and	O
explained	O
and	O
the	O
consent	O
form	O
signed	O
by	O
the	O
participant	O
of	O
the	O
project	O
investigator	O
at	O
the	O
latest	O
the	O
day	O
of	O
the	O
inclusion	O

Allergy	B
,	O
sensitivity	B
,	O
or	O
absolute	O
contraindications	B
to	O
any	O
of	O
the	O
medications	B
involved	O
in	O
the	O
study	B

preexisting	O
CNS	B
depression	I
,	O
or	O
taking	O
regularly	O
medication	B
that	O
cause	O
CNS	B
depression	I

preexisting	O
cognitive	B
deficits	I
,	O
dementia	B
,	O
or	O
delirium	B

severe	B
respiratory	B
comorbidities	I
(	O
e	O
.	O
g	O
.	O
chronic	B
obstructive	I
pulmonary	I
disease	I
,	O
pneumonia	B
,	O
respiratory	B
failure	I
)	O

sleep	B
disordered	I
breathing	I
(	O
diagnosed	O
OSA	B
,	O
obesity	B
hypoventilation	I
syndrome	I
)	O

pregnancy	O
and	O
breast	O
feeding	O

history	O
of	O
chronic	B
pain	I
or	O
regular	O
(	O
at	B
least	I
once	I
daily	I
)	O
opioid	B
use	O
preoperatively	B

renal	B
impairment	I
-	O
CrCl	B
=	B
60	I
mL	I
/	I
minute	I

not	O
fluent	O
in	O
English	O
to	O
be	O
able	O
to	O
participate	O
in	O
the	O
study	O
process	O
,	O
including	O
consent	O
and	O
phone	O
interview	O

Body	B
Mass	I
Index	I
>	B
35	I

inability	O
to	O
take	O
oral	B
medication	I
.	O

Age	B
18	B
-	I
65	I

scheduled	O
to	O
receive	O
ISB	B
and	O
general	B
anesthesia	I
as	O
a	O
day	B
surgery	I
patient	O
for	O
rotator	B
cuff	I
repair	I
and	O
acromioplasty	B
,	O
as	O
a	O
part	O
of	O
planned	O
routine	O
care	O

Contraindication	B
to	O
antiplatelet	B
therapy	I

Need	O
to	O
continue	B
clopidogrel	B
due	O
to	O
stroke	B
,	O
peripheral	B
disease	I
,	O
significant	B
carotid	B
disease	I
or	O
recent	B
acute	B
coronary	I
syndrome	I

Major	B
bleeding	B
history	B
or	O
bleeding	B
diathesis	I

Pregnancy	B

Age	B
19	B
and	I
more	I

On	O
dual	O
or	O
triple	B
antiplatelet	I
therapy	I
and	O
between	O
12months	O
and	O
14months	O
from	O
Bioresorbable	B
Vascular	I
Scaffold	I
implantation	B

No	B
history	B
of	O
death	B
,	O
serious	B
myocardial	B
infarction	I
,	O
stroke	B
,	O
repeat	B
revascularization	B
,	O
or	O
major	B
bleeding	B

Atypical	B
Parkinsonian	B
Syndromes	I

Parkinson	B
'	I
s	I
disease	I
with	O
hallucinations	B

Parkinson	B
'	I
s	I
disease	I
with	O
impulse	B
Control	I
disorder	I
(	I
ICD	I
)	I

Parkinson	B
'	I
s	I
disease	I
already	O
treated	O
with	O
APOMORPHINE	B
pump	O
or	O
justifying	O
the	O
use	O
of	O
the	O
pump	O
continuously	O
day	O
and	O
night	O

Another	O
obvious	O
severe	B
disease	I
explaining	O
insomnia	B

Exclusion	O
for	O
monitoring	O
difficulties	O
(	O
mutation	O
,	O
insufficient	O
motivation	O
,	O
priority	O
associated	O
pathology	O
in	O
care	O
)	O

Patient	O
unwilling	B
to	O
accept	O
a	O
pump	B

Patient	O
not	B
accepting	O
polysomnography	B
and	O
multiple	B
sleep	I
latency	I
test	I

Patient	O
with	O
health	B
problems	I
or	O
a	O
skin	B
disease	I
precluding	B
continuous	B
subcutaneous	I
infusion	I

Female	B
parturient	B
or	O
nursing	B

Cardiac	B
dysrhythmia	I
precluding	B
treatment	O
with	O
domperidone	B
or	O
apomorphine	B
(	O
increased	O
QTc	B
=	B
440	I
ms	I
in	O
men	B
,	O
QTc	B
=	B
450	I
ms	I
in	O
women	B
)	O

antiemetic	B
neuroleptics	I

Tetrabenazine	B

Excessive	B
alcohol	I
consumption	I

Hypersensitivity	B
to	O
apomorphine	B
or	O
one	O
of	O
the	O
excipients	B

Respiratory	B
Depression	I

Hepatic	B
impairment	I

Intellectual	B
Disability	I

Dementia	B

Idiopathic	B
Parkinson	B
'	I
s	I
disease	I
(	O
Hughes	O
AJ	O
et	O
al	O
.	O
2001	O
)	O

Patients	O
with	O
motor	B
fluctuations	I

Chronic	B
Insomnia	I
disorder	I
criteria	O
according	O
to	O
the	O
criteria	B
of	I
DMS	I
-	I
V	I
(	O
American	O
Psychiatric	O
Association	O
,	O
2013	O
)	O
and	O
insomnia	B
severity	I
index	I
>	B
15	I

Able	O
to	O
use	O
independently	O
the	O
device	B
required	O
for	O
treatment	O
by	O
apomorphine	B

Collection	O
of	O
written	O
informed	O
consent	O
(	O
legal	O
obligation	O
for	O
any	O
project	O
under	O
the	O
public	O
health	O
law	O
,	O
bioethics	O
laws	O
and	O
/	O
or	O
CNIL	O
)	O
.	O

Affiliate	B
to	I
social	I
security	I
or	O
beneficiary	O
of	O
such	O
a	O
regime	O

Patients	O
with	O
previous	O
periorbital	O
/	O
forehead	B
surgery	I

Patients	O
who	O
plucked	B
the	I
upper	I
eyebrow	I
margin	I

Patients	O
with	O
eyebrow	O
tatoos	O

Patients	O
with	O
upper	B
face	I
botulinum	B
toxin	I
injection	I
in	B
the	I
past	I
12	I
months	I

Patients	O
with	O
resorbable	O
upper	B
face	I
fillers	O
injection	O
in	B
the	I
past	I
12	I
months	I

Patients	O
with	O
previous	O
permanent	O
upper	B
face	I
fillers	O
injection	O

Pregnant	B
patients	O

Lactating	B
patients	O

Patients	O
with	O
preexisting	O
neuromuscular	B
conditions	I
(	O
myasthenia	B
gravis	I
,	O
Eaton	B
Lambert	I
syndrome	I
)	O

Patients	O
using	O
medication	B
that	O
could	O
potentiate	B
the	I
effect	I
of	O
botulinum	B
(	O
ex	O
:	O
aminoglycoside	B
antibiotics	I
)	O

Patients	O
with	O
sensitivity	B
to	O
botulinum	B
toxin	I
or	O
human	B
albumin	I

Consecutive	O
30	B
female	B
patients	O
presenting	O
to	O
our	O
clinic	O
for	O
brow	B
lifting	I
with	O
botulinum	B
toxin	I
will	O
be	O
randomized	O
to	O
receive	O
one	O
of	O
the	O
two	O
injection	O
techniques	O

Contraindication	B
for	O
propofol	B
administration	O

Contraindication	B
for	O
IAP	B
measurement	I
in	O
supine	B
position	I
with	O
head	B
-	I
of	I
-	I
bed	I
at	I
0	I
°	I

Other	B
intervention	B
for	I
reduction	I
of	I
IAP	I
planned	O

Previous	B
propofol	B
infusion	I
rate	I
>	B
4	I
mg	I
/	I
kg	I
/	I
h	I

Age	B
18	B
years	I
or	I
older	I

Mechanical	B
ventilation	I

IAP	B
between	B
12	I
and	I
20	I
mmHg	I
in	O
at	B
least	I
two	I
consecutive	I
measurements	I
within	B
1	I
-	I
12	I
h	I

Spontaneous	B
breathing	I
activity	I
of	O
at	B
least	I
6	I
breaths	I
/	I
minute	I

RASS	B
score	I
between	B
0	I
and	I
-	I
4	I

Physician	B
-	I
led	I
sedation	B
(	O
if	O
sedated	O
;	O
as	B
opposed	I
to	I
nurse	B
-	I
led	I
protocol	I
)	O

NA	O

Severe	B
or	O
uncontrolled	B
infection	B
.	O

Sensitive	B
to	O
the	B
product	I
or	O
other	B
genetically	B
engineered	I
biological	I
products	I
from	O
Escherichia	B
coli	I
strains	I
.	O

Mental	O
or	O
nervous	B
system	I
disorders	I
.	O

Severe	B
heart	O
,	O
lung	O
and	O
central	B
nervous	I
system	I
disorders	I
.	O

Pregnant	B
or	O
lactating	B
women	B
.	O

TBIL	B
(	O
total	B
bilirubin	I
)	O
,	O
ALT	B
(	O
alanine	B
aminotransferase	I
)	O
,	O
AST	B
(	O
glutamic	B
-	I
oxalacetic	I
transaminase	I
)	O
>	B
2	I
.	I
5	I
×	I
ULN	I
(	O
upper	O
limit	O
of	O
normal	O
)	O
;	O
if	O
it	O
were	O
caused	O
by	O
liver	B
metastases	I
,	O
TBIL	B
,	O
ALT	B
,	O
AST	B
>	B
5	I
×	I
ULN	I
.	O

Cr	B
(	O
creatinine	B
)	O
>	B
1	I
.	I
5	I
×	I
ULN	I
.	O

Patients	O
who	O
are	O
unwilling	O
to	O
participate	O
in	O
the	O
study	O
.	O
For	O
the	O
one	O
under	O
guardianship	O
,	O
the	O
refusal	O
of	O
the	O
patient	O
will	O
be	O
the	O
final	O
decision	O
even	O
if	O
the	O
guardian	O
is	O
willing	O
to	O
participate	O
.	O

Subjects	O
who	O
are	O
unlikely	O
to	O
adhere	O
to	O
the	O
study	O
an	O
/	O
or	O
poor	O
adherence	O
anticipated	O
by	O
the	O
investigator	O
.	O

Un	O
-	O
controlled	O
progressive	O
pathology	O
.	O

Osteoarticular	B
lesion	I
which	O
contraindicates	O
part	O
of	O
the	O
rehabilitation	O
involved	O
in	O
the	O
study	O
.	O

Patients	O
with	O
other	O
interventions	O
planned	O
prior	O
to	O
the	O
end	O
of	O
the	O
study	O
period	O
(	O
orthosis	O
,	O
surgery	O
etc	O
.	O
)	O
.	O

Surgery	B
to	O
the	O
treated	B
limb	I
less	B
than	I
6	I
months	I
previously	O
.	O

Pregnant	O
woman	O
.	O

Males	B
and	O
females	B
aged	B
between	B
18	I
to	I
75	I
years	I
.	O

Adult	O
patient	O
under	O
guardianship	O
with	O
consent	O
obtained	O
and	O
the	O
legal	O
guardian	O
'	O
s	O
authorisation	O
obtained	O
.	O

Single	B
stroke	B
having	O
occurred	O
more	B
than	I
6	I
months	I
before	O
(	O
previous	O
TIA	B
is	O
accepted	O
)	O
.	O

Capable	O
of	O
understanding	O
instructions	O
and	O
participating	O
in	O
the	O
definition	O
of	O
a	O
therapeutic	O
goal	O
(	O
Boston	B
Diagnostic	I
Aphasia	I
Examination	I
(	O
BDAE	B
)	O
<	B
3	I
)	O
.	O

Having	O
previously	O
undergone	O
BTI	B
.	O

The	O
last	O
injection	B
must	O
have	O
been	O
performed	O
at	B
least	I
4	I
months	I
prior	I
to	I
inclusion	I
.	O

Affiliation	O
to	O
the	O
French	O
social	O
security	O
regime	O
or	O
a	O
similar	O
regime	O
.	O

Patient	O
(	O
or	O
the	O
legal	O
guardian	O
if	O
under	O
guardian	O
adult	O
patient	O
)	O
has	O
signed	O
the	O
informed	O
consent	O
form	O
.	O

The	O
use	O
of	O
beta	B
blockers	I
within	B
2	I
months	I
of	I
randomization	I

Patients	O
actively	O
listed	O
for	O
transplantation	B
at	B
time	I
of	I
entry	I
into	I
the	I
study	I
or	O
anticipated	O
to	O
undergo	O
heart	B
transplantation	I
,	O
interventional	B
catheterization	I
,	O
or	O
corrective	B
cardiac	I
surgery	I
during	B
the	I
7	I
months	I
following	I
entry	I
into	I
the	I
study	I

Sustained	B
or	O
symptomatic	B
ventricular	B
dysrhythmias	I
uncontrolled	O
by	O
drug	B
therapy	O
or	O
the	O
use	O
of	O
an	O
implantable	B
defibrillator	I
,	O
and	O
/	O
or	O
significant	B
cardiac	B
conduction	I
defects	I
,	O
e	O
.	O
g	O
.	O
,	O
2nd	O
degree	O
or	O
3rd	B
degree	I
AV	I
block	I
,	O
or	O
sick	B
sinus	I
syndrome	I
,	O
unless	B
a	O
functioning	B
pacemaker	B
is	O
in	O
place	O

Uncorrected	B
obstructive	O
or	O
severe	B
regurgitant	B
valve	I
disease	I
,	O
nondilated	B
cardiomyopathy	I
,	O
or	O
significant	B
systemic	B
ventricular	I
outflow	I
obstruction	I

Known	O
renovascular	B
hypertension	I
or	O
evidence	O
of	O
pulmonary	B
hypertension	I
(	O
pulmonary	B
vascular	I
resistance	I
>	B
6	I
Wood	I
units	I
)	O
unresponsive	O
to	O
vasodilator	B
agents	I
such	O
as	O
oxygen	B
,	O
nitroprusside	B
,	O
or	O
nitric	B
oxide	I

History	B
or	O
current	B
clinical	O
evidence	O
of	O
moderate	B
-	I
to	I
-	I
severe	I
fixed	B
obstructive	B
pulmonary	I
disease	I
or	O
severe	B
reactive	B
airway	I
diseases	I
(	O
e	O
.	O
g	O
.	O
,	O
asthma	B
)	O
requiring	O
hospitalization	B
within	B
the	I
past	I
2	I
years	I
or	O
patient	O
currently	B
using	O
long	B
-	I
term	I
inhaled	I
bronchodilators	I

Renal	B
,	O
hepatic	B
,	O
gastrointestinal	B
,	O
or	O
biliary	B
disorder	B
that	O
could	O
impair	B
absorption	I
,	O
metabolism	O
or	O
excretion	O
of	O
orally	B
administered	I
medication	I

Concurrent	B
terminal	B
illness	I
or	O
other	B
severe	B
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
active	B
neoplasm	B
)	O
or	O
other	O
significant	O
laboratory	B
value	O
(	O
s	O
)	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
could	O
preclude	O
participation	O
or	O
survival	O

Endocrine	B
disorders	I
such	O
as	O
primary	B
aldosteronism	I
,	O
pheochromocytoma	B
,	O
hyper	O
-	O
or	O
hypothyroidism	B
,	O
insulin	B
-	I
dependent	I
diabetes	B
mellitus	I

Unwillingness	O
or	O
inability	O
to	O
cooperate	O
,	O
or	O
for	O
the	O
parents	O
or	O
guardians	O
to	O
give	O
consent	O
,	O
or	O
for	O
the	O
child	O
to	O
give	O
assent	O
,	O
or	O
any	O
condition	O
of	O
sufficient	O
severity	O
to	O
impair	O
cooperation	O
in	O
the	O
study	O

Pregnancy	B
or	O
possible	O
pregnancy	B
at	B
time	I
of	I
randomization	I
,	O
or	O
female	B
of	O
child	O
bearing	O
potential	O
who	O
are	O
lactating	O
,	O
or	O
sexually	O
active	O
and	O
not	B
taking	O
adequate	B
contraceptive	O
precautions	O
(	O
e	O
.	O
g	O
.	O
,	O
intrauterine	B
device	I
or	O
oral	B
contraceptives	I
for	B
3	I
months	I
prior	I
to	I
entry	I
into	I
the	I
study	I
)	O

Use	O
of	O
an	O
investigational	B
drug	I
within	B
30	I
days	I
of	I
randomization	I
,	O
or	O
within	O
5	O
half	O
-	O
lives	O
of	O
the	O
investigational	B
drug	I
(	O
the	O
longer	O
period	O
will	O
apply	O
)	O

History	B
of	O
drug	B
sensitivity	I
or	O
allergic	B
reaction	I
to	O
alpha	B
-	I
blockers	I
or	O
beta	B
-	I
blockers	I

Use	O
of	O
any	O
of	O
the	O
following	O
medications	O
within	B
two	I
weeks	I
of	I
randomization	I
:	O
MAO	B
inhibitors	I
,	O
Calcium	B
channel	I
blockers	I
,	O
alpha	B
blockers	I
,	O
beta	B
blockers	I
,	O
disopyramide	B
,	O
flecainide	B
,	O
encainide	B
,	O
moricizine	B
,	O
propafenone	B
,	O
sotalol	B
,	O
or	O
beta	B
adrenergic	I
agonists	I

Hospital	B
admission	I
for	O
protein	B
losing	I
enteropathy	I
or	O
plastic	B
bronchitis	I
within	B
3	I
months	I
of	I
randomization	I

Active	B
and	O
/	O
or	O
chronic	B
protein	B
losing	I
enteropathy	I
or	O
plastic	B
bronchitis	I
(	O
on	O
inhaled	B
medication	I
to	O
control	O
the	O
plastic	O
bronchitis	O
)	O
.	O

Hypoalbuminemia	B
defined	O
as	O
serum	B
albumin	I
<	B
2	I
.	I
0g	I
/	I
dL	I

Renal	B
dysfunction	I
defined	O
as	O
serum	B
creatinine	I
>	B
2	I
.	I
0mg	I
/	I
dL	I

Hepatic	B
dysfunction	I
defined	O
as	O
serum	B
AST	I
and	O
/	O
or	O
ALT	O
>	B
3	I
times	I
upper	I
limit	I
of	I
normal	I
(	O
approximately	B
120	I
IU	I
/	I
L	I
however	O
,	O
will	O
vary	O
depending	O
on	O
age	O
)	O
,	O

Significant	B
anemia	B
or	O
polycythemia	B
defined	O
as	O
hemoglobin	B
>	B
18gm	I
/	I
dL	I
or	O
hemoglobin	B
<	B
7gm	I
/	I
dL	I

Severely	B
elevated	I
serum	B
BNP	I
defined	O
as	O
BNP	B
>	B
300pg	I
/	I
ml	I

Informed	O
consent	O
of	O
parent	O
(	O
s	O
)	O
or	O
legal	O
guardian	O
;	O
informed	O
consent	O
or	O
assent	O
of	O
subject	O
as	O
applicable	O
.	O

Male	B
or	O
female	B
children	B
between	O
the	O
ages	B
of	O
10	O
and	O
35	O
years	O
with	O
congenital	B
heart	I
disease	I
that	O
has	O
been	O
palliated	O
with	O
a	O
Fontan	B
circulation	I
.	O

Ability	O
of	O
perform	O
a	O
maximal	B
exercise	I
test	I
as	O
defined	O
by	O
a	O
respiratory	B
exchange	I
ratio	I
(	I
RER	I
)	I
greater	B
than	I
1	I
.	I
0	I
at	B
the	I
time	I
of	I
maximal	I
exercise	I

AJCC	B
Stage	B
III	I
or	I
greater	I

Undifferentiated	O
,	O
Anaplastic	O
or	O
Medullary	B
Thyroid	I
Cancer	I

Planned	O
postoperative	B
TSH	B
goal	O
other	B
than	I
0	B
.	I
1	I
-	I
0	I
.	I
5	I
mU	I
/	I
L	I

History	O
of	O
gastrointestinal	B
malabsorption	I
or	O
gastric	B
bypass	I
surgery	I

Pregnancy	O

Use	O
of	O
medications	B
that	O
alter	B
the	O
absorption	O
or	O
metabolism	O
of	O
levothyroxine	B

Prior	B
use	O
of	O
levothyroxine	B

Age	B
>	B
18	I
years	I

Presumed	O
AJCC	O
(	O
American	B
Joint	I
Committee	I
on	I
Cancer	I
)	O
tumor	O
Stage	O
I	B
or	O
II	B

Planned	O
total	B
or	O
near	B
-	I
total	I
thyroidectomy	B

Planned	O
goal	O
TSH	B
suppression	I
0	B
.	I
1	I
-	I
0	I
.	I
5	I
mU	I
/	I
L	I
for	O
at	B
least	I
18	I
weeks	I
postoperatively	I

Normal	B
serum	B
TSH	I
within	B
12	I
months	I
preceding	I
surgery	I

Unable	O
to	O
give	O
informed	O
consent	O
in	O
English	O

Unable	O
to	O
complete	O
surveys	O
in	O
English	O

Unable	O
to	O
understand	O
instructions	O
for	O
using	O
pump	O
in	O
English	O

Unavailable	O
for	O
followup	O

Polytrauma	B
;	O
undergoing	O
other	B
surgeries	I
or	O
having	O
other	B
orthopedic	I
injuries	I
related	O
to	O
the	O
precipitating	O
cause	O
of	O
the	O
ankle	B
fracture	I

Infection	B

Peripheral	B
vascular	I
disease	I

Diabetes	B

Currently	O
undergoing	O
chemotherapy	B

Pregnancy	B

Currently	O
lactating	O

Heart	B
disease	I
or	O
heart	B
rhythm	I
disorder	I
or	O
taking	O
anti	B
-	I
arrhythmic	I
drugs	I

Severe	B
renal	I
impairment	I
(	O
Class	O
3	O
or	O
worse	O
kidney	O
disease	O
)	O

Liver	B
disease	I
(	O
cirrhosis	B
or	O
liver	B
failure	I
)	O

Prior	O
allergic	B
reaction	I
to	O
any	O
type	O
of	O
local	B
anesthetic	I

Taking	O
therapeutic	B
doses	O
of	O
anti	B
-	I
coagulants	I
or	O
anti	B
-	I
platelet	I
therapy	I
(	O
prophylactic	B
doses	O
started	O
because	O
of	O
hospital	O
admission	O
are	O
not	B
an	O
exclusion	O
)	O

Currently	O
taking	O
antidepressants	B
or	O
other	O
psychiatric	B
medications	I

Single	B
shot	I
local	B
nerve	I
block	I
prior	B
to	I
surgery	I
was	O
ineffective	O

Selected	O
for	O
neuraxial	B
anesthesia	I
rather	B
than	I
general	B
anesthesia	I
for	O
the	O
open	B
reduction	I
surgery	I

Already	O
receiving	O
chronic	B
analgesic	B
therapy	I
for	O
a	O
separate	B
chronic	B
pain	I
condition	O

Referred	O
for	O
surgery	B
for	O
open	B
reduction	I
and	I
internal	I
fixation	I
for	O
ankle	B
fracture	I

BMI	B
>	B
30	I
kg	I
.	I
m	I
-	I
2	I
,	O

ASA	B
physical	I
state	I
>	B
II	I

Allergy	B
to	O
the	O
used	O
local	B
anesthetics	I

Infection	B
at	O
the	O
injection	B
site	I

age	B
<	B
18y	I

Adult	B
patients	O
scheduled	O
for	O
arthroscopic	B
knee	I
ligament	I
reconstruction	I

Contraindication	B
for	O
IR	B
-	I
MPH	I
use	O

Current	B
stimulant	B
treatment	I

Evidence	O
of	O
a	O
clinically	B
significant	I
neurological	B
disease	I
that	O
might	B
affect	I
cognition	I
(	O
e	O
.	O
g	O
.	O
,	O
delirium	B
,	O
dementia	B
,	O
epilepsy	B
,	O
head	B
trauma	I
,	O
and	O
multiple	B
sclerosis	I
)	O

Current	B
or	O
past	B
history	B
of	O
psychosis	B

Estimated	B
intelligence	I
quotient	I
score	I
lower	B
than	I
70	I

White	B
Brazilian	B
of	O
European	B
descent	I

Fulfillment	O
of	O
the	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
Fourth	I
Edition	I
,	I
(	I
DSM	I
-	I
IV	I
)	I
diagnostic	I
criteria	I
for	O
ADHD	B

Eligibility	O
to	O
immediate	B
-	I
release	I
MPH	I
(	I
IR	I
-	I
MPH	I
)	I
treatment	O

Having	O
experienced	O
severe	B
allergies	I
,	O
trauma	B
history	O
and	O
/	O
or	O
operation	B
history	O
within	B
3	I
months	I
;	O

With	O
a	O
history	B
of	O
mental	B
illness	I
and	O
/	O
or	O
family	O
history	O
of	O
mental	B
illness	I
;	O

Limb	B
disabled	I
;	O

Taking	O
medicine	B
within	B
one	I
month	I
;	O

Suffering	O
major	B
events	I
or	O
having	O
mood	B
swings	I
.	O

Women	B
aged	B
20	B
-	I
49	I
;	O

Having	O
a	O
regular	B
menstrual	I
cycle	I
of	O
which	O
the	O
menstrual	B
period	I
is	O
between	B
day	I
3	I
-	I
7	I
,	O
and	O
the	O
period	O
between	B
day	I
25	I
-	I
35	I
;	O

Excluding	O
internal	O
and	O
surgical	B
disease	I
(	O
after	O
having	O
variety	O
of	O
physical	O
examination	O
such	O
as	O
electrocardiogram	O
/	O
hepatic	O
and	O
renal	O
function	O
/	O
blood	O
routine	O
and	O
urine	O
routine	O
)	O
.	O

Subjects	O
under	O
the	O
age	B
of	O
21	O
.	O

Subjects	O
with	O
excessively	B
thin	I
corneas	I
.	O

Subjects	O
with	O
topographic	B
evidence	I
of	O
keratoconus	B
.	O

Subjects	O
with	O
ectatic	B
eye	I
disorders	I
.	O

Subjects	O
with	O
autoimmune	B
diseases	I
.	O

Subjects	O
who	O
are	O
pregnant	B
or	O
nursing	B
.	O

Subjects	O
age	B
21	B
and	I
older	I

Subjects	O
with	O
healthy	B
eyes	I

Subjects	O
who	O
have	O
previously	B
undergone	O
LASIK	B
surgery	I

Subjects	O
with	O
residual	B
refractive	I
error	I
.	O

Heart	B
failure	I

Signs	O
of	O
kidney	B
injury	I
/	O
failure	O

Severe	B
allergies	B

For	O
healthy	B
individuals	O
:	O
Healthy	B
,	O
without	B
allergies	B
and	O
with	O
the	O
age	B
of	O
18	B
years	I
or	I
above	I
.	O

For	O
patients	B
:	O
Burn	B
injury	I
exceeding	O
6	O
-	O
8	O
Total	B
Burned	I
Surface	I
Area	I
%	O

Fasting	B
plasma	I
glucose	I
>	B
7	I
,	I
0	I
mM	I
,	O
HbA1c	B
>	B
48	I
mmol	I
/	I
mol	I
3	B
months	I
after	I
RYGB	I

Dysregulated	B
thyroid	B
diseases	I
,	O
use	O
of	O
antithyroid	B
treatment	I
.	O

Late	B
diabetic	I
complications	I
as	O
retinopathy	B
,	O
renal	B
insufficiency	I
,	O
neuropathy	B
or	O
previous	B
pancreatitis	B
.	O

Complications	B
to	O
RYGB	B
.	O

Documented	O
reactive	B
hypoglycaemia	I
,	O
severe	B
dumping	B
(	O
vomiting	B
,	O
diarrhea	B
,	O
severe	B
abdominal	B
pain	I
after	B
food	I
intake	I
)	O

Cholecystectomy	B
.	O

Uncomplicated	B
RYGB	B
performed	O
minimum	B
3	I
months	I
prior	I
to	I
the	I
study	I
.	O

Fasting	B
glucose	I
<	B
7	I
,	I
0	I
mM	I
,	O
HbA1c	B
<	B
48	I
mmol	I
/	I
mol	I
3	O
months	O
after	O
RYGB	B

NA	O

At	B
least	I
18	I
years	I
of	O
age	B

Signed	O
informed	O
consent	O

African	B
American	I
race	B

History	O
of	O
a	O
solitary	B
renal	B
transplant	I

Stable	O
tacrolimus	B
dose	O
for	B
at	I
least	I
2	I
weeks	I
prior	I
to	I
randomization	I

congenital	B
or	O
acquired	B
bleeding	B
tendency	I

platelet	B
count	I
<	B
50	I
,	I
000	I
/	I
µL	I

hypersensitivity	B
to	O
shrimps	B
,	O
lobsters	B
or	O
beetles	B

age	B
18	B
years	I
or	I
older	I

patients	O
undergoing	B
invasive	B
procedures	I
via	O
the	O
radial	O
or	O
femoral	B
arteries	I

patients	O
who	O
do	O
not	O
wish	O
to	O
participate	O
in	O
the	O
project	O
;	O

patients	O
with	O
ectopic	B
pregnancy	I
;	O

patients	O
with	O
comorbidities	B
(	O
heart	B
failure	I
congestive	I
,	O
chronic	B
obstructive	I
pulmonary	I
disease	I
)	O
;	O

patients	O
with	O
hypovolemic	B
shock	I
;	O

patients	O
with	O
cervical	B
incompetence	I
;	O

patients	O
with	O
infected	B
miscarriage	B
/	O
abortion	B
(	O
presence	O
of	O
fever	B
,	O
pus	B
from	I
the	I
cervix	I
,	O
leukocytosis	B
[	O
>	B
14000	I
]	O
)	O
;	O

patients	O
with	O
twin	B
pregnancy	B
;	O

patients	O
with	O
Marfan	B
syndrome	I
;	O

patients	O
allergic	B
to	O
misoprostol	B
;	O

patients	O
with	O
coagulopathy	B
;	O

patients	O
with	O
opening	O
of	O
cervical	O
internal	O
os	O
(	O
4	B
mm	I
of	I
dilatation	I
at	O
the	O
time	O
of	O
consultation	O
)	O
;	O

patients	O
with	O
previous	O
surgery	B
of	O
the	O
cervix	B
(	O
conization	B
)	O
;	O

patients	O
with	O
concomitant	O
use	O
of	O
IUDs	B
.	O

All	O
patients	O
admitted	O
at	O
the	O
Gynecological	O
emergency	O
Unit	O
at	O
Hospital	O
de	O
Clínicas	O
de	O
Porto	O
Alegre	O
scheduled	O
for	O
uterine	B
evacuation	I
with	O
<	B
12	I
weeks	I
of	O
gestation	B
.	O

History	O
of	O
intolerance	B
to	O
LMWHs	B
during	O
HD	B

Receiving	O
warfarin	B
or	O
other	B
oral	B
anticoagulant	I

Pregnant	B
patients	O

Prevalent	O
NHHD	B
patients	O
who	O
have	O
received	O
>	B
1	I
year	I
dialysis	B
with	O
unfractionated	B
heparin	I
as	O
anticoagulant	B

Age	B
>	B
=	I
18	I

Informed	O
consent	O
available	O

Hemoglobin	B
concentration	I
under	B
6	I
.	I
5	I
mmol	I
/	I
l	I
screening	O

HBA1c	B
more	B
than	I
108	I
mmol	I
/	I
l	I

Non	B
-	I
compliant	I
with	O
blood	B
-	I
letting	I

Clinically	O
infected	B
ulcer	I

Patient	O
planned	O
for	O
or	O
has	O
had	O
a	O
revascularization	B
procedure	I
in	O
the	O
affected	O
leg	O
within	B
the	I
last	I
8	I
weeks	I

The	O
ulcer	B
have	O
been	O
treated	B
with	O
growth	B
factors	I
in	B
the	I
last	I
8	I
weeks	I

History	B
of	O
deep	B
venous	I
insufficiency	I
,	O
chronic	B
venous	I
leg	I
ulcer	I
or	O
stasis	B
dermatitis	I

Breast	B
-	I
feeding	I
women	B
or	O
fertile	B
women	B
not	B
agreeing	O
to	O
use	O
an	O
effective	O
method	O
of	O
contraception	O

Participation	O
in	O
another	O
clinical	O
ulcer	O
-	O
healing	O
study	O
within	O
the	O
last	O
4	O
weeks	O

Patient	O
has	O
previously	O
been	O
randomized	O
in	O
this	O
study	O

Judgement	O
by	O
the	O
investigator	O
that	O
the	O
patient	O
is	O
not	O
able	O
to	O
participate	O
in	O
the	O
study	O

Diabetes	B
mellitus	I

Foot	B
ulcer	I
at	O
the	O
malleoli	B
area	I
between	B
0	I
,	I
25	I
cm²	I
and	I
5	I
,	I
0	I
cm²	I

Foot	B
ulcer	I
duration	O
more	B
than	I
6	I
weeks	I

Ankle	B
-	I
brachial	I
index	I
above	B
0	I
,	I
40	I
or	O
presence	O
of	O
palpable	B
pulses	I
in	O
arteria	O
dorsalis	O
pedes	O
and	O
/	O
or	O
arteria	O
tibialis	O
posterior	O

informed	O
consent	O

History	O
of	O
constipation	B

Pre	B
-	I
existing	I
use	O
of	O
narcotics	B
or	O
opioids	B

Pre	B
-	I
existing	I
renal	O
or	O
hepatic	B
failure	I

Mental	B
illness	I
,	O
mental	B
retardation	I
,	O
or	O
inability	B
to	I
participate	I
in	I
informed	I
consent	I
due	O
to	O
mental	B
status	I

Pre	B
-	I
existing	I
dementia	B

Allergy	B
to	O
any	O
protocol	O
medication	O

Emergency	B
operation	B

Subjects	O
who	O
are	O
incarcerated	O
or	O
wards	O
of	O
the	O
state	O

Minors	B

Subjects	O
with	O
inflammatory	B
bowel	I
disease	I
,	O
active	B
colitis	B
,	O
or	O
pre	B
-	I
existing	I
intra	B
-	I
abdominal	I
inflammation	I
.	O

Diverticulitis	B
without	B
active	B
infection	B
/	O
inflammation	B
will	O
not	B
be	I
excluded	I
.	O

Males	B
or	O
females	B
above	O
the	O
age	B
of	O
18	O

Patients	O
undergoing	O
laparoscopic	B
or	O
robotic	B
colorectal	B
resections	I

Breast	B
Carcinoma	I

Idiopathic	B
Granulomatous	I
Mastitis	I

presence	O
of	O
subacute	B
or	O
chronic	B
DVT	B
more	B
than	I
21	I
days	I
in	I
duration	I
,	O
inability	B
to	I
lie	I
in	I
the	I
prone	I
position	I
required	O
for	O
intervention	O
,	O
terminal	B
systemic	I
disease	I
requiring	O
palliative	B
treatment	I
,	O
active	B
bleeding	B
(	O
from	O
a	O
gastric	O
/	O
duodenal	B
ulcer	I
or	O
the	O
cerebrovascular	B
system	I
)	O
,	O
a	O
haemorrhagic	B
stroke	I
within	B
the	I
previous	I
year	I
,	O
an	O
impaired	B
bleeding	I
-	I
clotting	I
profile	I
,	O
and	O
any	O
haemophilic	B
disorder	I
,	O
or	O
pregnancy	B
.	O

proven	B
acute	B
deep	B
venous	I
thrombosis	I
,	O
less	B
than	I
21	I
days	I
and	O
who	O
were	O
referred	O
to	O
the	O
interventional	O
radiology	O
department	O
.	O

Obstructed	B
outlet	I
syndrome	I
(	O
objectified	O
by	O
defeacography	B
)	O

Irritable	B
bowel	I
syndrome	I
(	O
Rome	B
-	I
IV	I
criteria	I
for	O
irritable	B
bowel	I
syndrome	I
)	O

Congenital	O
or	O
organic	B
bowel	I
pathology	I

Rectal	B
prolapse	I

Anatomical	O
limitations	O
preventing	B
placement	B
of	I
an	I
electrode	I

Skin	O
and	O
perineal	B
disease	I
with	O
risk	O
of	O
infection	O

Previous	O
large	O
bowel	O
/	O
rectal	B
surgery	I

Stoma	B

Coexisting	O
neurological	B
disease	I

Significant	B
psychological	B
co	I
-	I
morbidity	I
as	O
assessed	O
subjectively	O
by	O
the	O
investigator	O

Being	O
or	O
attempting	O
to	O
become	O
pregnant	O
during	O
study	O
follow	O
-	O
up	O

An	O
average	B
defecation	I
frequency	I
(	O
DF	B
)	O
of	O
<	B
3	I
per	I
week	I
based	O
on	O
a	O
3	B
-	I
week	I
defecation	I
diary	I
(	O
patient	B
-	I
reported	I
)	O

Meet	O
at	B
least	I
one	I
other	B
criterion	B
of	O
the	O
Rome	O
-	O
IV	O
criteria	O
for	O
idiopathic	B
constipation	I
based	O
on	O
the	O
3	B
-	I
week	I
defecation	I
diary	I
(	O
1	O
)	O

Refractory	B
to	O
conservative	B
treatment	I

Age	B
:	O
14	B
-	I
80	I
years	I

Straining	B
during	O
=	B
25	I
%	I
of	O
defecations	B

Lumpy	O
or	O
hard	O
stools	O
in	O
=	B
25	I
%	I
of	O
defecations	B

Sensation	B
of	I
incomplete	I
evacuation	I
for	O
=	B
25	I
%	I
of	O
defecations	B

Sensation	B
of	I
anorectal	I
obstruction	I
/	O
blockage	O
for	O
=	B
25	I
%	I
of	O
defecations	B

Manual	B
manoeuvres	I
to	O
facilitate	O
=	B
25	I
%	I
of	O
defecations	B

Known	O
or	O
suspected	O
gram	B
-	I
negative	I
infections	B
,	O
anaerobic	B
infections	B
,	O
or	O
fungemia	B

Known	O
or	O
suspected	O
infections	B
that	O
are	O
severe	B
,	O
life	B
threatening	I
or	O
are	O
not	O
included	O
in	O
the	O
ABSSSI	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
guidance	O

Injection	O
drug	B
users	I
with	O
a	O
fever	B

Severe	B
neurological	B
disorder	I
leading	O
to	O
immobility	O
or	O
confined	O
to	O
a	O
wheelchair	B

Bilateral	B
Lower	I
extremity	I
involvement	O
of	O
the	O
suspected	O
infection	B
.	O

Presents	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
and	O
meets	O
the	O
clinical	O
definition	O
for	O
Acute	B
Bacterial	I
Skin	I
and	I
Skin	I
Structure	I
Infections	I
(	O
ABSSSI	B
)	O

Known	O
or	O
suspected	O
gram	B
-	I
positive	I
infection	B
.	O

Patients	O
with	O
a	O
history	O
of	O
allergy	B
or	O
hypersensitivity	B
to	O
tramadol	B
.	O

History	O
of	O
epilepsy	B
or	O
convulsions	B
due	O
to	O
any	O
reason	O
.	O

Chronic	O
usage	O
of	O
analgesic	B
drugs	I
.	O

Patients	O
using	O
monoamine	B
oxidase	I
inhibitors	I
.	O

Patients	O
with	O
clinical	O
signs	O
of	O
raised	B
ICP	B
.	O

Obesity	B
(	O
women	B
with	O
a	O
body	B
mass	I
index	I
>	B
35	I
kg	I
/	I
m2	I
or	O
men	B
with	O
a	O
body	B
mass	I
index	I
>	B
42	I
kg	I
/	I
m2	I
)	O

Language	O
barrier	O
.	O

Patients	O
taking	O
B	B
-	I
blockers	I
or	O
Ca	B
channel	I
blockers	I
.	O

Patients	O
above	B
65	I
years	I
of	O
age	B
(	O
Physiology	O
difference	O
)	O

Patients	O
with	O
craniotomy	B
for	O
supratentorial	B
tumors	I
under	O
general	B
anesthesia	I

American	B
Society	I
of	I
Anaesthesiologists	I
(	O
ASA	B
)	O
2	B
and	O
stable	B
ASA	B
3	B
patients	O

Elective	B
surgery	I

Patients	O
with	O
Glasgow	B
Coma	I
Scale	I
(	O
GCS	B
)	O
15	B
/	I
15	I

eGFR	B
<	B
45	I
ml	I
/	I
min	I

structural	B
and	O
functional	B
urogenital	B
abnormalities	I
,	O
that	O
predispose	O
for	O
urogenital	B
infections	I

Investigational	B
product	I
use	I
in	B
the	I
last	I
6	I
months	I

SGLT2	B
inhibitor	I
,	O
TZD	B
,	O
DPP4	B
inhibitor	I
and	O
GLP1	B
RA	I
use	O
within	B
the	I
past	I
6	I
months	I

DKA	B
(	O
Diabetic	B
Ketoacidosis	I
)	O
or	O
HHS	B
(	O
Hyperosmoloar	B
Hyperglycaemic	I
Syndrome	I
)	O
within	B
the	I
last	I
6	I
months	I

Pregnancy	O

Presence	O
of	O
major	O
contraindications	O
to	O
magnetic	B
resonance	I
imaging	I
(	O
cardiac	B
pacemakers	I
,	O
claustrophobia	B
,	O
foreign	O
bodies	O
and	O
implanted	B
medical	I
devices	I
with	O
ferromagnetic	B
properties	I
)	O
.	O

Liver	B
cirrhosis	I

Type	B
1	I
diabetes	I

Severe	B
uncorrected	B
insulin	B
insufficiency	I

Significant	B
alcohol	O
intake	O

HIV	B
infection	I

Use	O
of	O
Traditional	B
Chinese	I
Medication	I
or	O
alternative	B
therapies	I

Coexisting	O
causes	O
of	O
chronic	B
liver	I
disease	I
-	O
chronic	B
viral	I
hepatitis	I
(	I
B	I
&	O
C	O
)	O
,	O
autoimmune	B
liver	I
disease	I
,	O
hemochromatosis	B
,	O
Wilson	B
'	I
s	I
etc	O
.	O

Use	O
of	O
medications	B
associated	O
with	O
steatosis	B
eg	O
.	O

Methotrexate	B
,	O
anticonvulsants	B
,	O
antiretroviral	B
therapy	I
etc	O
.	O

h	O
/	O
o	O
stroke	B

Steroid	B
therapy	I

Endogenous	B
Cushing	B
'	I
s	I

Familial	B
hypertriglyceridemia	I

biopsy	B
proven	O
NASH	B

Type	B
2	I
DM	I

HbA1c	B
:	O
>	B
6	I
.	I
5	I
%	I

BMI	B
<	B
45kg	I
/	I
m2	I

Any	O
anti	B
-	I
diabetic	I
agent	I
except	B
SGLT2	B
inhibitors	I
,	O
TZDs	B
(	O
thiazolidinediones	B
)	O
,	O
DPP4	O
(	O
Dipeptidyl	B
peptidase4	I
)	I
inhibitors	I
and	O
GLP1	B
RAs	I
(	O
Glucagon	B
-	I
like	I
Peptide	I
1	I
-	I
Receptor	I
Agonists	I
)	O

Participation	O
in	O
other	O
interventional	O
research	O
.	O

History	O
of	O
penetrating	B
head	I
injury	I

History	O
of	O
TBI	B
more	B
severe	I
than	I
mild	I
by	O
DVBIC	B
criteria	I

Diagnosis	O
of	O
a	O
primary	B
or	O
secondary	B
HA	B
disorder	I
other	B
than	I
PTHA	B

Lifetime	B
history	I
of	O
5	B
or	I
more	I
migraine	B
or	O
probable	B
migraine	B
headaches	O
pre	O
-	O
dating	O
mTBI	B

HAs	B
of	O
any	O
kind	O
of	O
moderate	B
or	I
severe	I
intensity	I
on	O
an	O
average	B
of	I
more	I
than	I
2	I
days	I
per	I
month	I
preceding	B
the	I
concussive	I
trauma	I

Continuous	B
HAs	B
of	O
any	O
kind	O
(	O
i	O
.	O
e	O
.	O
,	O
persistent	B
daily	B
HAs	B
with	O
no	B
HA	O
-	O
free	O
period	O
less	B
than	I
8	I
hours	I
between	O
attacks	O
)	O

Acute	B
or	O
serious	B
medical	B
illness	I
or	O
unstable	B
chronic	B
medical	I
illness	I
(	O
e	O
.	O
g	O
.	O
,	O
unstable	B
angina	I
,	O
myocardial	B
infarction	I
within	B
6	I
months	I
,	O
congestive	B
heart	I
failure	I
,	O
clinically	B
significant	I
or	O
concerning	B
cardiac	B
arrhythmias	I
;	O
preexisting	B
hypotension	B
[	O
systolic	B
blood	I
pressure	I
<	B
110	I
]	O
or	O
orthostatic	B
hypotension	I
[	O
systolic	B
drop	I
>	B
20	I
mm	I
Hg	I
after	B
2	I
min	I
standing	I
accompanied	O
by	O
lightheadedness	B
]	O
,	O
chronic	O
renal	O
or	O
hepatic	B
failure	I
,	O
acute	B
pancreatitis	I
,	O
Meniere	B
'	I
s	I
disease	I
,	O
or	O
diagnosed	O
but	O
untreated	B
sleep	B
apnea	I
)	O
.	O

The	O
eligibility	O
of	O
potential	O
participants	O
having	O
acute	O
serious	O
and	O
/	O
or	O
chronic	O
medical	O
illnesses	O
other	O
than	O
those	O
listed	O
will	O
be	O
evaluated	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
by	O
a	O
study	O
physician	O
,	O
PA	O
-	O
C	O
,	O
or	O
ARNP	O
.	O

Use	O
of	O
prazosin	B
or	O
other	B
alpha	B
-	I
1	I
antagonist	I
(	O
including	O
but	O
not	O
limited	O
to	O
alfuzosin	B
,	O
doxazosin	B
,	O
silodosin	B
,	O
tamsulosin	B
,	O
terazosin	B
)	O
for	O
any	O
purpose	O
in	B
the	I
2	I
weeks	I
prior	I
to	I
initial	I
screen	I
(	I
P1	I
)	I
visit	I
and	O
prohibited	O
throughout	O
the	O
study	O

Allergy	B
or	O
previous	B
adverse	B
reaction	I
to	O
prazosin	B
or	O
other	B
alpha	B
-	I
1	I
antagonist	I

Active	B
psychosis	B
or	O
psychotic	B
disorder	I
,	O
severe	B
depression	I
(	O
as	O
determined	O
per	O
clinician	O
prescriber	O
judgment	O
)	O
,	O
severe	B
psychiatric	B
instability	I
or	O
severe	B
situational	B
life	I
crisis	I
(	O
including	O
evidence	O
of	O
being	O
actively	O
suicidal	B
or	O
homicidal	B
)	O
.	O

Meets	B
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
5th	I
Edition	I
(	I
DSM	I
-	I
5	I
)	I
criteria	I
for	O
any	O
Substance	B
Use	I
Disorder	I
except	B
caffeine	B
-	I
related	I
disorders	I
,	O
or	O
tobacco	B
-	I
related	I
disorders	I
.	O

History	O
of	O
delirium	B
within	B
the	I
prior	I
3	I
months	I
,	O
epilepsy	B
,	O
stroke	B
,	O
dementia	B
,	O
psychotic	B
disorder	I
,	O
or	O
bipolar	B
disorder	I

Structural	B
brain	I
abnormalities	I
on	O
any	B
prior	B
imaging	B
with	O
associated	O
clinically	B
evident	I
manifestations	B

Current	B
participation	O
in	O
transcranial	B
magnetic	I
stimulation	I
studies	I

Women	B
of	O
childbearing	B
potential	I
must	O
not	B
be	I
pregnant	B
,	O
planning	O
to	O
become	O
pregnant	B
during	B
the	I
study	I
period	I
,	O
or	O
nursing	B
.	O

Participation	B
in	I
a	I
HA	I
support	I
group	I
or	O
other	O
activity	O
such	O
as	O
meditation	B
or	O
yoga	B
intended	O
to	O
mitigate	O
HA	O
or	O
other	O
chronic	O
pain	O
must	O
be	O
stable	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
beginning	O
the	O
initial	O
screen	O
(	O
P1	O
)	O
visit	O
and	O
may	O
not	O
be	O
started	O
during	O
the	O
study	O

Failure	O
to	O
record	O
HA	O
data	O
for	B
at	I
least	I
80	I
%	I
of	I
days	I
during	B
the	I
Screening	I
Period	I

Not	O
suitable	O
for	O
study	O
per	O
clinician	O
judgement	O
.	O

The	O
use	O
of	O
HA	O
rescue	O
or	O
symptom	O
-	O
relieving	O
medications	O
will	O
be	O
allowed	O
during	O
the	O
study	O
.	O
This	O
includes	O
triptans	O
,	O
ergotamines	O
,	O
opioids	O
,	O
simple	O
analgesics	O
(	O
e	O
.	O
g	O
.	O
acetaminophen	O
,	O
aspirin	O
,	O
or	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatories	O
[	O
NSAIDS	O
]	O
,	O
and	O
combination	O
analgesics	O
.	O
Their	O
use	O
will	O
be	O
recorded	O
on	O
the	O
concurrent	O
medication	O
CRF	O
during	O
the	O
Preliminary	O
Screening	O
Period	O
(	O
P1	O
)	O
and	O
throughout	O
the	O
remainder	O
of	O
the	O
study	O
.	O
Randomization	O
of	O
participants	O
will	O
be	O
stratified	O
based	O
on	O
whether	O
their	O
use	O
of	O
HA	O
medications	O
meets	O
ICHD	O
-	O
3	O
beta	O
criteria	O
for	O
overuse	O
of	O
these	O
medications	O
,	O
as	O
described	O
in	O
section	O
5	O
.	O
5	O
below	O
.	O

Opioid	O
Medications	O
:	O
Use	O
of	O
opioids	O
for	O
treatment	O
of	O
HA	O
or	O
non	O
-	O
HA	O
-	O
related	O
pain	O
or	O
for	O
any	O
other	O
purpose	O
is	O
allowed	O
during	O
the	O
study	O
.	O
Any	O
opioid	O
use	O
would	O
ideally	O
be	O
excluded	O
due	O
to	O
potential	O
confounding	O
effects	O
on	O
interpretation	O
of	O
response	O
to	O
treatment	O
.	O
However	O
,	O
in	O
this	O
population	O
,	O
particularly	O
in	O
Veterans	O
with	O
chronic	O
pain	O
or	O
undergoing	O
minor	O
orthopedic	O
or	O
dental	O
procedures	O
,	O
opioid	O
use	O
is	O
common	O
.	O
Use	O
of	O
opioids	O
,	O
including	O
frequency	O
and	O
dose	O
,	O
will	O
be	O
recorded	O
on	O
the	O
concurrent	O
medication	O
CRF	O
.	O

Other	O
Medications	O
:	O
Participants	O
who	O
are	O
taking	O
other	B
medications	B
on	B
a	I
routine	I
basis	I
must	O
be	O
on	O
a	O
stable	B
dose	I
for	B
at	I
least	I
4	I
weeks	I
prior	I
to	I
the	I
Preliminary	I
Screening	I
Period	I
(	I
P1	I
)	I
,	O
and	O
must	O
intend	O
to	O
continue	O
the	O
medication	O
at	O
the	O
same	O
regimen	O
for	O
the	O
duration	O
of	O
the	O
trial	O
unless	O
lack	O
of	O
efficacy	O
,	O
safety	O
,	O
or	O
tolerability	O
dictates	O
otherwise	O
.	O

The	O
following	O
medications	O
are	O
not	O
excluded	O
:	O

Psychoactive	O
drugs	O
(	O
for	O
example	O
,	O
anticonvulsants	O
,	O
benzodiazepines	O
,	O
antidepressants	O
,	O
sedative	O
/	O
hypnotics	O
)	O
,	O

Antihypertensive	O
medications	O
(	O
including	O
beta	O
-	O
blockers	O
,	O
calcium	O
channel	O
blockers	O
,	O
angiotensin	O
converting	O
enzyme	O
[	O
ACE	O
]	O
inhibitors	O
,	O
and	O
angiotensin	O
receptor	O
blockers	O
)	O
,	O

The	O
use	O
of	O
magnesium	O
in	O
any	O
dose	O
that	O
is	O
prescribed	O
for	O
the	O
purpose	O
of	O
HA	O
prevention	O
or	O
treatment	O
must	O
be	O
stable	O
for	O
at	O
least	O
4	O
weeks	O
.	O
The	O
incidental	O
use	O
of	O
magnesium	O
in	O
multi	O
-	O
vitamins	O
,	O
laxatives	O
,	O
etc	O
.	O
is	O
permissible	O
but	O
must	O
be	O
documented	O
.	O

Hormones	O
(	O
for	O
example	O
,	O
testosterone	O
,	O
estrogen	O
,	O
or	O
progesterone	O
)	O
in	O
any	O
form	O
.	O

The	O
"	O
as	O
-	O
needed	O
"	O
(	O
prn	O
)	O
use	O
of	O
psychoactive	O
and	O
other	O
drugs	O
such	O
as	O
antibiotics	O
is	O
not	O
excluded	O
;	O
however	O
,	O
such	O
use	O
must	O
be	O
discussed	O
with	O
a	O
clinician	O
prescriber	O
and	O
documented	O
.	O

The	O
use	O
of	O
butalbital	B
in	O
any	O
form	O
within	B
4	I
weeks	I
of	I
beginning	I
the	I
Preliminary	I
Screening	I
Period	I
(	I
P1	I
)	I
through	O
the	O
end	O
of	O
the	O
participant	O
'	O
s	O
study	O
involvement	O
is	O
exclusionary	O
.	O

Participants	O
who	O
have	O
been	O
taking	O
trazodone	O
will	O
undergo	O
a	O
2	O
-	O
week	O
washout	O
period	O
before	O
the	O
Preliminary	O
Screening	O
Period	O
(	O
P1	O
visit	O
)	O
.	O
Combining	O
prazosin	O
and	O
trazodone	O
may	O
increase	O
the	O
risk	O
of	O
priapism	O
.	O
We	O
have	O
decided	O
to	O
begin	O
the	O
washout	O
period	O
before	O
the	O
Preliminary	O
Screening	O
Period	O
in	O
order	O
to	O
remove	O
any	O
confounding	O
variables	O
while	O
on	O
the	O
headache	O
log	O
and	O
actigraphy	O
.	O

Sildenafil	B
(	O
Viagra	B
)	O
,	O
tadalafil	B
(	O
Cialis	B
)	O
,	O
vardenafil	B
(	O
Levitra	B
)	O
,	O
and	O
avanafil	B
(	O
Stendra	B
)	O
will	O
not	O
be	O
permitted	O
during	B
the	I
study	I
drug	I
dose	I
Titration	I
Period	I
,	O
because	O
of	O
increased	O
risk	O
of	O
hypotension	O
in	O
combination	O
with	O
alpha	O
-	O
1	O
blockers	O
,	O
but	O
will	O
be	O
allowed	O
at	O
half	O
the	O
usual	O
starting	O
dose	O
following	O
the	O
study	O
drug	O
dose	O
Titration	O
Period	O
,	O
per	O
VA	O
prescribing	O
guidelines	O
.	O

Use	O
of	O
supplements	O
containing	O
nitrates	B
and	O
supplements	O
containing	O
stimulants	B
(	O
such	O
as	O
ephedra	B
)	O
are	O
exclusionary	O
in	B
the	I
two	I
weeks	I
prior	I
to	I
initial	I
screen	I
(	I
P1	I
)	I
visit	I
and	O
prohibited	O
throughout	O
the	O
study	O
.	O

Participants	O
who	O
take	O
these	O
supplements	O
will	O
be	O
asked	O
to	O
discontinue	O
them	O
for	O
a	O
minimum	O
of	O
two	O
weeks	O
before	O
the	O
Preliminary	O
Screening	O
Period	O
(	O
P1	O
visit	O
)	O
.	O
.	O

Use	O
of	O
prescribed	B
stimulants	I
(	O
such	O
as	O
amphetamine	B
or	O
dextroamphetamine	B
containing	O
medications	O
)	O
is	O
exclusionary	O
in	B
the	I
2	I
weeks	I
prior	I
to	I
the	I
initial	I
screen	I
(	I
P1	I
)	I
visit	I
and	O
prohibited	O
throughout	O
the	O
study	O
.	O

Participants	O
who	O
take	O
these	O
medications	O
will	O
be	O
asked	O
to	O
discontinue	O
them	O
for	O
a	O
minimum	O
of	O
2	O
weeks	O
before	O
the	O
Preliminary	O
Screening	O
Period	O
.	O

Male	B
and	O
female	B
Active	B
-	I
duty	I
SMs	I
or	O
Veterans	B
aged	B
18	B
or	I
older	I
who	O
are	O
in	O
good	B
general	I
health	I
.	O

History	B
of	I
blast	O
and	O
/	O
or	O
impact	B
head	I
trauma	I
mTBI	O
meeting	B
Defense	B
and	I
Veterans	I
Brain	I
Injury	I
Center	I
(	I
DVBIC	I
)	I
mTBI	I
criteria	I
,	O
which	O
define	O
mTBI	O
as	O
an	O
injury	O
to	O
the	O
head	O
causing	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
alteration	B
in	I
consciousness	I
(	O
for	B
up	I
to	I
24	I
hours	I
after	I
the	I
injury	I
)	O
,	O
loss	B
of	I
consciousness	I
0	B
-	I
30	I
minutes	I
,	O
and	O
/	O
or	O
post	B
-	I
traumatic	I
amnesia	I
up	B
to	I
1	I
day	I
post	I
-	I
injury	I
.	O

If	O
available	O
,	O
the	O
Glasgow	B
Coma	I
Scale	I
score	O
must	O
be	O
13	B
-	I
15	I
,	O
and	O
head	B
imaging	I
findings	B
(	O
if	O
imaging	O
was	O
performed	O
)	O
must	O
be	O
negative	B
.	O

Frequent	B
HAs	B
that	O
started	O
within	B
3months	I
after	I
a	I
head	I
injury	I
.	O

The	O
HAs	B
either	O
1	O
)	O
must	O
last	B
4	I
or	I
more	I
hours	I
a	I
day	I
and	O
reach	O
a	O
moderate	B
to	I
severe	I
intensity	I
at	O
any	O
point	O
during	O
the	O
headache	O
,	O
or	O
2	O
)	O
may	O
be	O
of	O
any	O
severity	O
or	O
duration	O
if	O
the	O
participant	O
takes	O
a	O
triptan	B
or	O
ergotamine	B
.	O

HAs	O
meeting	O
these	O
criteria	O
must	O
have	O
been	O
present	O
on	O
average	O
at	B
least	I
8	I
days	I
per	I
4	I
-	I
week	I
period	I
,	O
starting	O
within	B
30	I
days	I
after	I
head	I
injury	I
and	O
occurring	O
by	O
self	O
-	O
report	O
for	O
at	B
least	I
3	I
months	I
prior	I
to	I
the	I
Initial	I
Screening	I
Visit	I
.	O

The	O
4	O
-	O
week	O
HA	O
frequency	O
/	O
severity	O
criteria	O
must	O
be	O
confirmed	O
during	O
the	O
Preliminary	O
Screening	O
Period	O
.	O

Women	O
of	O
childbearing	O
potential	O
must	O
agree	O
to	O
abstain	O
from	O
sexual	O
relations	O
that	O
could	O
result	O
in	O
pregnancy	O
or	O
use	O
an	O
effective	O
method	O
of	O
birth	O
control	O
acceptable	O
to	O
both	O
participant	O
and	O
the	O
clinician	O
prescriber	O
during	O
the	O
study	O
.	O
Men	O
are	O
not	O
required	O
to	O
use	O
contraception	O
during	O
the	O
study	O
.	O

Participants	O
must	O
have	O
English	O
fluency	O
sufficient	O
to	O
complete	O
study	O
measures	O
.	O

Use	O
of	O
any	O
oral	B
antidiabetic	I
treatment	O
except	B
for	I
metformin	B
(	O
i	O
.	O
e	O
.	O
,	O
sulphonylureas	B
,	O
DPP	B
-	I
IV	I
inhibitors	I
,	O
thiazolidinediones	B
,	O
SGLT	B
-	I
2	I
inhibitors	I
(	O
Sodium	O
dependent	O
glucose	O
transporter	O
)	O
or	O
GLP	B
-	I
1	I
analogues	I
(	O
glucagone	O
like	O
peptide	O
)	O
within	B
the	I
last	I
three	I
months	I
prior	I
to	I
Screening	I

Repeated	B
episodes	O
of	O
severe	B
hypoglycaemia	I
within	B
the	I
last	I
six	I
months	I
prior	I
to	I
Screening	I

History	B
of	O
diabetic	B
ketoacidosis	I
,	O
precoma	B
diabetica	I
,	O
or	O
diabetic	B
coma	I

Treatment	B
with	O
any	O
other	O
investigational	B
drug	I
within	B
the	I
last	I
three	I
months	I
before	I
Screening	I

Acute	B
infections	I
within	B
the	I
last	I
four	I
weeks	I
prior	I
to	I
Screening	I

Recurrent	B
urogenital	B
infections	I

History	B
of	O
pancreatitis	B

Anamnestic	B
history	I
of	O
hypersensitivity	B
to	O
the	O
study	B
drugs	I
or	O
to	O
drugs	B
with	I
similar	I
chemical	I
structures	I

History	B
of	O
severe	B
or	O
multiple	B
allergies	B

Concomitant	B
participation	O
in	O
other	O
clinical	O
trials	O

Type	B
1	I
diabetes	I

Cardiovascular	B
disease	I
Clinically	B
relevant	I
ventricular	B
tachycardia	I
or	O
ventricular	B
fibrillation	I
,	O
3rd	B
degree	I
AV	I
block	I
or	O
Torsades	B
de	I
Pointes	I
or	O
treatment	B
with	O
antiarrhythmic	B
drugs	I
.	O

Percutaneous	B
coronary	I
intervention	I
within	B
the	I
past	I
6	I
months	I
.	O

Any	O
of	O
the	O
following	O
within	B
the	I
past	I
6	I
months	I
:	O
myocardial	B
infarction	I
(	I
MI	I
)	I
,	O
coronary	B
artery	I
bypass	I
surgery	I
;	O
unstable	B
angina	I
;	O
or	O
stroke	B
.	O

Malignancy	B
including	O
leukemia	B
and	O
lymphoma	B
within	B
the	I
last	I
5y	I
.	O

Liver	B
disease	I
such	O
as	O
cirrhosis	B
or	O
chronic	B
active	I
hepatitis	I
.	O

Significant	B
renal	B
dysfunction	I
(	O
see	O
also	O
exclusion	O
criteria	O
laboratory	O
abnormalities	O
)	O
.	O

State	O
after	O
kidney	B
transplantation	I

Endocrine	B
disease	I
:	O

Systolic	B
blood	I
pressure	I
outside	B
the	I
range	I
of	I
100	I
-	I
160	I
mmHg	I
or	O
diastolic	B
blood	I
pressure	I
above	B
95	I
mmHg	I
at	B
Screening	I

History	B
of	O
active	B
substance	B
abuse	I
(	O
including	O
alcohol	B
>	B
40g	I
/	I
day	I
)	O
within	B
the	I
past	I
2	I
years	I
.	O

Pregnancy	B
or	O
childbearing	O
potential	O
without	B
adequate	B
contraception	B

Present	B
therapy	B
with	O
systemic	B
steroids	I

Presence	O
of	O
psychiatric	B
disorder	I
or	O
intake	O
of	O
anti	O
-	O
depressive	O
or	O
anti	B
-	I
psychotic	I
agents	I
with	B
the	I
exception	I
of	I
benzodiazepines	B
and	O
SSRIs	B
/	O
SNRI	B
'	I
s	I
(	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
)	O

Potentially	O
unreliable	O
subjects	O
,	O
and	O
those	O
judged	O
by	O
the	O
investigator	O
to	O
be	O
unsuitable	O
for	O
the	O
study	O
.	O

Contraindications	B
for	O
Magnetic	B
resonance	I
(	I
MR	I
)	I
scanning	I
such	O
as	O
persons	O
with	O
cardiac	B
pacemaker	I
and	O
implants	B
out	I
of	I
metal	I
or	O
claustrophobia	B

Type	B
2	I
diabetes	I

Age	B
18	B
-	I
75	I
years	I

Anti	O
-	O
GAD	O
antibodies	O
negative	B
(	O
Glutamic	O
Acid	O
Decarboxylase	O
)	O

C	B
-	I
peptide	I
levels	I
=	B
1	I
.	I
5	I
ng	I
/	I
mL	I

Fasting	B
blood	I
glucose	I
>	B
126	I
mg	I
/	I
dl	I

HbA1c	B
8	B
.	I
0	I
-	I
10	I
.	I
5	I
%	I

BMI	B
25	B
.	I
0	I
-	I
45	I
.	I
0	I
kg	I
/	I
m2	I

Previous	B
therapy	B
with	O
BBIT	B
(	O
basal	B
insulin	I
and	I
at	I
least	I
once	I
daily	I
bolus	I
insulin	I
)	O

Coronary	B
artery	I
disease	I
-	O
stent	B

Severe	B
chronic	B
renal	B
failure	I

Congenital	B
or	O
acquired	B
thrombophilia	B
/	O
thrombosis	B
event	I

Known	O
or	O
suspected	O
allergy	B

Complex	B
kidney	I
stone	I
(	O
staghorn	B
calculi	I
GUYS	B
III	B
and	I
IV	I
)	O

Medical	O
history	B
of	O
chronic	B
psychiatric	I
disease	I

Medical	B
conditions	I
associated	O
with	O
female	B
sexual	I
dysfunction	I
;	O
cardiovascular	B
disease	I
,	O
uncontrolled	B
chronic	B
HT	B
(	O
hypertension	B
)	O
,	O
DM	B
(	O
diabetes	B
mellitus	I
)	O
,	O
History	B
of	O
gynecologic	B
surgery	I
,	O
female	B
gynecological	I
cancer	I
(	O
breast	B
,	O
ovarian	B
,	O
uterine	B
,	O
cervical	B
)	O

Medications	B
associated	O
with	O
female	B
sexual	I
dysfunction	I
;	O
Antidepressants	B
opiates	B
,	O
beta	B
blockers	I
,	O
Antiepileptics	B
(	O
gabapentin	B
,	O
topiramate	B
,	O
phenytoin	B
)	O
benzodiazepines	B

Menopausal	B
status	O

Sexually	O
active	O

History	B
of	I
organic	B
brain	I
disease	I

DSM	B
-	I
IV	I
diagnosis	O
of	O
Alcohol	O
or	O
Substance	B
Dependence	I
within	B
the	I
last	I
six	I
months	I
(	O
except	B
nicotine	B
)	O
or	O
DSM	B
-	I
5	I
diagnosis	O
of	O
Substance	B
Use	I
Disorder	I
in	B
the	I
last	I
six	I
months	I
(	O
except	B
nicotine	B
)	O

DSM	B
-	I
IV	I
diagnosis	O
of	O
Alcohol	O
or	O
Substance	B
Abuse	I
within	B
the	I
last	I
one	I
month	I
(	O
except	B
nicotine	B
)	O
or	O
DSM	B
-	I
5	I
diagnosis	O
of	O
Substance	B
Use	I
Disorder	I
in	B
the	I
last	I
six	I
months	I
(	O
except	B
nicotine	B
)	O

Pregnancy	B
or	O
lactation	B

Severe	B
liver	B
dysfunction	I
(	O
LFT	B
3X	B
upper	I
limit	I
of	I
normal	I
)	O

Previous	B
known	O
hypersensitivity	B
to	O
tetracyclines	B

Current	B
treatment	B
with	O
tetracycline	B
or	O
derivative	O

Treatment	B
with	O
oral	B
contraceptives	I
(	O
unless	B
a	O
second	B
form	I
of	O
birth	O
control	O
is	O
used	O
and	O
documented	O
)	O

Treatment	B
with	O
cholestyramine	B
or	O
colestipol	B

Treatment	B
with	O
Urinary	B
alkalinizers	I
(	O
e	O
.	O
g	O
.	O
,	O
sodium	B
lactate	I
,	O
potassium	B
citrate	I
)	O

Treatment	B
with	O
warfarin	B

Treatment	B
with	O
bupropion	B
,	O
varenicline	B
,	O
or	O
nicotine	B
replacement	I
products	I
in	B
the	I
month	I
prior	I
to	I
study	I
inclusion	I

Less	B
than	I
two	I
months	I
treatment	B
of	O
adjunctive	B
medications	I
AND	O
less	B
than	I
one	I
month	I
on	O
same	B
dose	I
:	O
beta	B
blockers	I
,	O
antidepressants	B
,	O
mood	B
stabilizers	I
,	O
antianxiety	B
medications	I
.	O

Medical	B
condition	I
whose	O
pathology	O
or	O
treatment	O
would	B
significantly	I
increase	I
the	I
risk	I
associated	I
with	I
the	I
proposed	I
protocol	I
.	O

History	B
of	O
head	B
injury	I
,	O
seizures	B
,	O
or	O
stroke	B

Positive	B
urine	B
toxicology	I
screen	I
for	O
substances	B
of	I
non	I
-	I
therapeutic	I
use	I
prior	B
to	I
craving	I
assessments	I

DSM	B
-	I
IV	I
or	O
DSM	B
-	I
5	I
diagnosis	O
of	O
schizophrenia	B
or	O
schizoaffective	B
disorder	I

Male	B
or	O
Female	B

Age	B
:	O
18	B
to	I
65	I
years	I

Caucasian	B
or	O
Non	B
-	I
Caucasian	I

Smoke	O
at	B
least	I
10	I
cigarettes	I
daily	I

Urine	B
cotinine	I
level	I
?	B
100	I
ng	I
/	I
ml	I
(	O
NicAlert	B
(	I
r	I
)	I
reading	O
?	B
3	I
)	O

Agrees	O
to	O
wear	O
a	O
head	B
mounted	I
display	I
(	I
HMD	I
)	I
for	B
up	I
to	I
45	I
minutes	I

Able	O
to	O
complete	O
the	O
Evaluation	B
to	I
Sign	I
Consent	I
(	I
ESC	I
)	I
with	O
minimum	B
score	I
of	I
80	I
%	I

BMI	B
<	B
35	I
and	I
>	I
60	I
kg	I
/	I
m2	I

Inability	B
to	I
walk	I
(	O
bed	B
-	I
bound	I
or	O
wheelchair	B
dependence	I
)	O

open	B
abdominal	I
surgeries	I
except	B
simple	B
appendectomy	I
and	O
common	B
OB	I
/	I
GYN	I
procedures	I
in	O
the	O
pelvis	B
(	O
hysterectomy	B
,	O
C	B
-	I
section	I
,	O
and	O
oophorectomy	B
,	O
tubal	B
ligation	I
)	O

laparoscopic	O
bowel	O
or	O
solid	B
organ	I
resection	I
except	B
laparoscopic	B
cholecystectomy	I

ventral	B
hernia	I
repair	B
with	I
mesh	I

Preoperative	B
chronic	B
opiate	B
use	O
for	O
chronic	B
pain	I
defined	O
as	O
opiate	B
usage	O
at	B
least	I
60	I
mg	I
/	I
day	I
of	I
morphine	I
equivalent	I
for	B
=	I
3	I
months	I
(	O
as	O
defined	O
by	O
International	O
Association	O
for	O
the	O
Study	O
of	O
Pain22	O
)	O
in	O
the	O
one	O
year	O
period	O
prior	O
to	O
the	O
bariatric	B
surgery	I

The	O
American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
score	I
>	B
3	I

History	O
of	O
hypersensitivity	B
or	O
adverse	B
reaction	I
to	O
bupivacaine	B
or	O
narcotics	B

Inability	O
to	O
speak	O
English	O

ventral	B
hernia	I
repair	B

Cholecystectomy	B

hiatal	B
hernia	I
repair	B
with	O
posterior	B
cruroplasty	I

extensive	B
lysis	B
of	I
adhesions	I

other	O
procedures	O
that	O
mandate	O
addition	O
of	O
"	O
trocar	O
(	O
s	O
)	O
"	O
or	O
"	O
feeding	O
tube	O
"	O

Addition	O
of	O
trocar	B
(	O
s	O
)	O
or	O
conversion	O
of	O
surgery	B
to	O
hand	B
-	I
assisted	I
or	O
open	B

Fulfills	B
NIH	B
criteria	I
for	O
bariatric	B
surgery	I

Planned	O
operation	O
of	O
laparoscopic	B
Roux	I
-	I
en	I
Y	I
gastric	I
bypass	I
(	I
LRYGB	I
)	I
or	O
laparoscopic	B
sleeve	I
gastrectomy	I
(	I
LSG	I
)	I
as	O
primary	B
bariatric	O
procedure	O

NA	O

Meets	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
(	O
Versions	B
4	I
and	O
5	O
)	O
criteria	O
for	O
and	O
Major	B
Depressive	I
Disorder	I
.	O

Hamilton	B
Depression	I
Rating	I
Scale	I
-	O
17	O
score	O
greater	B
than	I
18	I
.	O

Men	B
and	O
women	B
between	O
ages	B
>	O
=	O
18	O
and	O
65	O
.	O

Any	O
anti	B
-	I
coagulation	I
therapy	I
(	O
apart	B
from	I
rivaroxaban	B
for	O
second	O
objective	O
)	O

Hypersensitivity	B
or	O
allergy	B
to	O
factor	B
Xa	I
inhibitors	I

Acute	B
bacterial	I
endocarditis	I

Bleeding	B
disorder	I

Clinically	O
relevant	O
active	B
bleeding	I

Gastrointestinal	B
ulcer	I
or	O
tumor	O

Hepatic	B
dysfunction	I
with	O
increased	B
bleeding	O
risk	O

Renal	B
failure	I
/	O
patients	O
undergoing	O
dialysis	B

Pregnancy	O
and	O
breast	O
feeding	O

Gastrectomy	B
,	O
biliopancreatic	B
diversion	I
,	O
resection	B
or	O
re	B
-	I
routing	I
of	O
small	B
intestines	I

Feeding	B
tube	I

Recent	O
blood	O
donation	O

Abnormalities	B
of	O
laboratory	O
values	O
:	O
alanine	B
-	I
aminotransferase	I
(	O
ALAT	B
)	O
,	O
aspartate	B
-	I
aminotransferase	I
(	O
ASAT	B
)	O
,	O
gamma	B
-	I
glutamyl	I
transferase	I
(	O
gammaGT	B
)	O
,	O
alkalic	B
phosphatase	I
(	O
AP	B
)	O
,	O
bilirubin	B
,	O
amylase	B
,	O
lipase	B
,	O
cystatin	B
C	I
,	O
creatinine	B
,	O
white	B
blood	I
cell	I
count	I
,	O
haemoglobin	B
,	O
platelet	B
count	I
,	O
prothrombin	B
time	I
,	I
aPTT	B
,	O
fibrinogen	B
,	O
thrombin	B
time	I
,	O
factors	B
II	I
,	O
V	O
,	O
VII	O
and	O
X	O

Use	O
of	O
therapeutic	O
or	O
recreational	O
drugs	O
influencing	O
plasmatic	O
coagulation	O

Motor	O
complete	B
tetraplegia	B
for	O
at	B
least	I
3	I
months	I

Age	B
from	B
18	I
to	I
74	I
years	I

Body	B
mass	I
index	I
(	O
BMI	B
)	O
from	B
18	I
to	I
35kg	I
/	I
m2	I

Informed	O
consent	O
as	O
documented	O
by	O
signature	O

Unwillingness	O
or	O
inability	O
to	O
comply	O
with	O
the	O
procedures	O
described	O
in	O
this	O
protocol	O

Planned	O
cardiac	B
surgery	I
or	O
planned	O
major	B
non	B
-	O
cardiac	B
surgery	B
within	B
the	I
study	I
period	I
.	O

Stroke	O
or	O
coronary	B
revascularization	I
in	B
the	I
past	I
6	I
months	I
.	O

Clinically	B
significant	I
pulmonary	B
disease	I
.	O

Untreated	B
hyperthyroidism	B
,	O
or	O
hypothyroidism	B
.	O

A	O
diagnosis	O
of	O
cancer	B
(	O
other	B
than	I
superficial	O
squamous	O
or	O
basal	B
cell	I
skin	I
cancer	I
)	O
in	B
the	I
past	I
3	I
years	I
or	O
current	O
treatment	B
for	O
the	O
active	B
cancer	B
.	O

Female	O
of	O
child	O
-	O
bearing	O
potential	O
who	O
do	O
not	O
use	O
adequate	O
contraception	O
and	O
women	O
who	O
are	O
pregnant	O
or	O
breast	O
-	O
feeding	O

Any	O
clinically	O
significant	O
abnormality	O
identified	O
at	O
the	O
screening	O
visit	O
,	O
physical	O
examination	O
,	O
laboratory	O
tests	O
,	O
or	O
electrocardiogram	O
which	O
,	O
in	O
the	O
judgment	O
of	O
the	O
Investigator	O
,	O
would	O
preclude	O
safe	O
completion	O
of	O
the	O
study	O
.	O

LV	B
ejection	I
fraction	I
<	B
50	I
%	I
.	O

Significant	B
renal	B
disease	I
manifested	O
by	O
serum	B
creatinine	I
>	B
2	I
.	I
5	I
mg	I
/	I
dL	I

Hepatic	B
disease	I
or	O
biliary	B
tract	I
obstruction	I
,	O
or	O
significant	B
hepatic	B
enzyme	I
elevation	I
(	O
ALT	B
or	O
AST	B
>	B
3	I
times	I
upper	I
limit	I
of	I
normal	I
)	O
.	O

History	O
of	O
intolerance	B
to	O
ARB	B
or	O
amlodipine	B
.	O

Hypertrophic	O
or	O
restrictive	B
cardiomyopathy	I
.	O

Moderate	B
or	O
severe	B
valvular	B
disease	I
.	O

Constrictive	B
pericarditis	I

Atrial	B
fibrillation	I
with	O
a	O
heart	B
rate	I
>	B
120	I
/	I
min	I
.	O

Sitting	B
systolic	B
BP	I
<	B
100	I
mmHg	I

Controlled	B
hypertension	B
:	O
systolic	B
BP	I
<	B
150	I
and	O
diastolic	B
BP	I
<	B
90	I
mmHg	I
in	O
persons	O
aged	B
60	B
years	I
or	I
older	I
,	O
systolic	B
BP	I
<	B
140	I
and	O
diastolic	B
BP	I
<	B
90	I
mmHg	I
in	O
persons	O
40	B
through	I
59	I
years	B
according	O
to	O
the	O
JNC	B
8th	I
guideline	I

Evidence	O
of	O
diastolic	B
dysfunction	I
showing	O
E	B
/	I
E	I
'	I
>	B
10	I

The	O
patient	O
agrees	O
to	O
the	O
study	O
protocol	O
and	O
the	O
schedule	O
of	O
clinical	O
and	O
echocardiographic	O
follow	O
-	O
up	O
,	O
and	O
provides	O
informed	O
,	O
written	O
consent	O
,	O
as	O
approved	O
by	O
the	O
appropriate	O
Institutional	O
Review	O
Board	O
/	O
Ethical	O
Committee	O
of	O
the	O
respective	O
clinical	O
site	O

no	O
consent	O

periprocedural	B
complications	I
requiring	O
continuation	O
of	O
heparin	B
or	O
administration	O
of	O
protamine	B
sulfate	I

alergy	B
to	O
fish	B
,	O
protamine	B
,	O
protamine	B
derivates	I
,	O
history	B
of	O
Humulin	B
N	I
,	O
Novolin	B
N	I
,	O
Novolin	B
NPH	I
,	O
Gensulin	B
N	I
,	O
SciLin	B
N	I
,	O
NPH	B
Iletin	I
II	I
and	O
isophane	B
insulin	I
intake	O

patients	O
who	O
underwent	O
successful	B
TAVI	B

with	O
any	O
approved	O
TAVI	B
device	I

via	O
transfemoral	B
access	I

with	O
use	O
of	O
any	O
of	O
the	O
approved	O
vascular	B
closure	I
devices	I

provided	O
written	O
informed	O
consent	O

Dual	B
organ	I
or	O
kidney	O
after	O
another	O
solid	B
organ	I
transplant	I

Presence	O
of	O
a	O
preexisting	B
significant	B
GI	B
condition	I
that	O
does	O
not	O
have	O
a	O
presumed	O
causal	O
relationship	O
with	O
MPA	O

Evidence	O
of	O
any	O
GI	B
disorder	I
induced	O
by	O
an	O
infection	B
,	O
underlying	B
medical	I
condition	I
,	O
or	O
concomitant	O
medication	B
other	B
than	I
MPA	B

eGFR	B
<	B
40	I
ml	I
/	I
min	I
at	B
time	I
of	I
possible	I
conversion	I

Proteinuria	B
>	B
1	I
gram	I
/	I
day	I
at	B
time	I
of	I
possible	I
conversion	I

Hemoglobin	B
<	B
10	I
g	I
/	I
dL	I

WBC	B
<	B
3	I
K	I
/	I
cumm	I

Platelets	B
<	B
100	I
K	I
/	I
cumm	I

Wound	B
healing	I
issues	I
at	B
time	I
of	I
possible	I
conversion	I
(	O
eg	O
,	O
wound	B
dehiscence	I
,	O
wound	B
infection	I
,	O
incisional	B
hernia	I
,	O
lymphocele	B
,	O
seroma	B
)	O

Elevated	B
total	B
cholesterol	I
(	O
>	B
350	I
mg	I
/	I
dL	I
)	O
and	O
/	O
or	O
triglycerides	B
(	O
>	B
500	I
ng	I
/	I
dL	I
)	O
at	B
time	I
of	I
possible	I
conversion	I

Hypersensitivity	B
to	O
everolimus	B
,	O
sirolimus	B
,	O
or	O
other	O
rapamycin	B
deriviatives	O

Kidney	B
transplant	I
recipients	O
at	O
Washington	O
University	O
/	O
Barnes	O
-	O
Jewish	O
Hospital	O

Experiencing	O
GI	B
toxicity	I
from	O
MPA	B
as	O
determined	O
by	O
the	O
treating	O
physician	O
within	O
12	O
months	O
post	O
-	O
renal	O
transplant	O

On	O
standard	B
immunosuppression	I
with	O
tacrolimus	B
and	O
prednisone	B

Signs	O
of	O
hemodynamic	B
instability	I
(	O
i	O
.	O
e	O
.	O
systolic	B
blood	I
pressure	I
<	B
100	I
mm	I
Hg	I
.	I
St	I
.	I
or	O
episode	O
of	O
systolic	B
blood	I
pressure	I
fall	I
for	O
=	B
40	I
mm	I
Hg	I
.	O
/	O
or	O
heart	B
rate	I
>	B
110	I
lasting	B
more	I
than	I
15	I
min	I
)	O
or	O
need	O
for	O
ventilatory	B
support	I
within	B
12	I
hours	I
prior	I
to	I
randomisation	I
.	O

The	O
indication	O
for	O
oral	B
anticoagulation	I
,	O
associated	O
with	O
others	O
disease	O
.	O

malignant	B
neoplasm	B
of	O
any	O
location	O

Contraindications	B
to	O
warfarin	B
or	O
pradaxa	B
according	O
to	O
Russian	B
Instructions	I
for	I
medical	I
use	I
of	O
these	O
drugs	O

Indications	O
for	O
concomitant	B
treatment	O
with	O
antiplatelet	B
agents	I

Any	O
stroke	B
within	B
6	I
months	I
before	I
randomization	I

Intracranial	B
hemorrhage	I
in	O
anamnesis	B

Active	B
bleeding	B
,	O
bleeding	B
diathesis	I
.	O

Clinically	B
significant	I
bleeding	B
within	B
the	I
last	I
30	I
days	I
.	O

Trauma	B
or	O
extensive	B
surgery	I
within	B
1	I
month	I
before	I
randomization	I
or	O
surgery	B
planned	O
in	B
the	I
next	I
6	I
months	I
after	I
randomization	I
.	O

Intracranial	B
pathology	I
:	O
tumor	B
,	O
arteriovenous	B
fistula	I
or	O
aneurysm	B
.	O

Gastrointestinal	B
bleeding	I
in	B
the	I
previous	I
3	I
months	I
.	O

Gastric	B
ulcer	I
or	O
duodenal	B
ulcer	I
with	O
clinical	B
manifestations	I
or	O
endoscopically	B
identified	O
acute	B
ulcer	I
without	B
signs	B
of	I
scarring	I
during	B
previous	I
30	I
days	I
.	O

Uncontrolled	B
hypertension	B
(	O
systolic	B
blood	I
pressure	I
>	B
180	I
mm	I
Hg	I
.	O
and	O
/	O
or	O
diastolic	B
blood	I
pressure	I
>	B
100	I
mm	I
.	I
hg	I
in	O
patients	O
receiving	O
antihypertensive	B
drugs	I
)	O
.	O

Pregnancy	B
,	O
lactation	B
.	O

Life	O
expectancy	O
<	B
6	I
months	I
.	O

Clinically	B
significant	I
liver	B
disease	I
.	O

Creatinine	B
clearance	I
(	O
estimated	O
by	O
Cockcroft	B
-	I
Gault	I
)	O
<	B
30	I
ml	I
/	I
min	I
.	O

hemoglobin	B
level	I
<	B
90	I
g	I
/	I
l	I
)	O
,	O
thrombocytopenia	B
<	B
100x10	I
^	I
9	I
/	I
L	I
.	O

Patients	O
who	O
,	O
in	O
the	O
opinion	O
of	O
the	O
researcher	O
,	O
are	O
not	O
suitable	O
for	O
inclusion	O
in	O
the	O
study	O
,	O
for	O
example	O
,	O
due	O
to	O
the	O
low	O
likelihood	O
of	O
doctor	O
'	O
s	O
recommendations	O
following	O
.	O

Long	B
-	I
term	I
use	I
of	O
NSAIDs	B

Current	O
participation	O
in	O
another	O
clinical	O
study	O
.	O

Allergic	B
to	O
contrast	B
substance	I
or	O
radioisotope	B
drugs	I
used	O
in	O
procedures	O
to	O
assess	O
endpoints	O
of	O
the	O
study	O
,	O
which	O
according	O
to	O
researchers	O
,	O
may	O
be	O
a	O
contraindication	O
to	O
the	O
implementation	O
of	O
these	O
research	O
methods	O
.	O

Men	B
and	O
women	B
aged	B
>	B
18	I
years	I

Angiographically	B
confirmed	O
acute	B
massive	B
pulmonary	B
embolism	I
with	O
involvement	B
of	I
Central	I
pulmonary	I
arteries	I
.	O

endovascular	B
mechanical	I
thrombus	I
fragmentation	I
+	O
thrombolytic	B
therapy	I
(	O
using	O
recombinant	B
tissue	I
activator	I
of	I
plasminogen	I
)	O
,	O
performed	O
for	O
treatment	B
of	O
the	O
above	O
-	O
mentioned	O
pulmonary	B
embolism	I
in	B
less	I
than	I
48	I
hours	I
before	I
randomization	I
.	O

The	O
patient	O
should	O
be	O
randomized	O
no	O
earlier	O
than	O
24	O
hours	O
after	O
procedures	O
endovascular	O
mechanical	O
thrombus	O
fragmentation	O
+	O
thrombolytic	O
therapy	O

Written	O
informed	O
consent	O
signed	O
by	O
patient	O
.	O

